CA2169298A1 - Uses of green fluorescent protein - Google Patents
Uses of green fluorescent proteinInfo
- Publication number
- CA2169298A1 CA2169298A1 CA002169298A CA2169298A CA2169298A1 CA 2169298 A1 CA2169298 A1 CA 2169298A1 CA 002169298 A CA002169298 A CA 002169298A CA 2169298 A CA2169298 A CA 2169298A CA 2169298 A1 CA2169298 A1 CA 2169298A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- protein
- green fluorescent
- fluorescent protein
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Abstract
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein. This invention also provides living organisms which comprise the above-described cell. This invention also provides a method for selecting cells expressing a protein of interest which comprises: a) introducing into the cells a DNAI molecule having DNA sequence encoding the protein of interest and DNAII molecule having DNA sequence encoding a green fluorescent protein; b) culturing the introduced cells under conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest. Finally, this invention provides various uses of a green fluorescent protein.
Description
PCT~S94/10165 W095/07463 2 ~ 6 ~ 2 9 8 USES OF GREEN FLUORESCENT PROTEIN
This application is a continuation-in-part of United States Application Serial Nos. 08/119,678 and 08/192,274, filed September 10, 1993 and February 4, 1994, respectively, the contents of which are hereby incorporated by reference.
The invention disclGsed here n was made with Government support under NIH Grant No. 5ROlGM30997 from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.
sac~o~d of the invention Throughout this application various references are referred to within parenthesis. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Full bibliographic citation for these references may be found at the end of this application, preceding the sequence listing and the claims.
Several methods are available to monitor gene activity and protein distribution within cells. These include the formation of fusion proteins with coding sequences for ~-galactosidase (22), and luciferases (22). The usefulness of these methods is often limited by the requirement to fix cell preparations or to add exogenous substrates or cofactors. This invention disclose a method of ex~mining gene expression and protein localizatlon in living cells that requires no exogenously-added compounds.
~ This method uses a cDNA encoding the Green fluorescent W095/07463 PCT~S94/10165 2~ 6~298 2 - ~
Protein (GFP) from the jelly fish Aequorea victoria (3 ) .
In A. victoria, GFP absorbs energy generated by aequori.n upon the stimulation by calcium and emits a green light.
This invention discloses that GFP expressed in prokaryotic and eukaryotic cells is capable of producing a strong green fluorescence when excited with near W or blue light. Since this fluorescence requires no additional gene products from A. victoria, chromophore formation is not species specific.
;: .~
W095/07463 2 1 6 q ~ ~ ~ PCT~S94110165 SummarY of the invention This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein. This invention also provides living organisms comprising the above-described cell.
This invention provides a method for selecting cells expressing a protein of interest which comprises: a) introducing into the cells a DNAI molecule having DNA
sequence encoding the protein of interest and DNAI I
molecule having DNA sequence encoding a green fluorescent protein; b) culturing the introduced cells in conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest.
This invention also provides a method for localizing a protein of interest in a cell: a) introducing into a cell a DNA molecule having DNA sequence encoding the protein 2~ of interest linked to DNA sequence encoding the green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein;
c) detecting the location of the fused protein product, thereby localizing the protein of interest.
f, W095/07463 PCT~S94/10165 ~ 69~q8 4 - ~
Brief Descri~tion of Fiqures Figure 1 Expression of GFP in E. coli. The bacteria on the right side of the figure have the GFP
expression plasmid. This photograph was taken while irradiating the agar plate with a hand-held long-wave W source.
Figure 2 Excitation and Emission Spectra of E. coli-generated GFP (solid lines) and purified A.
victoria GFP (L form; dotted lines).
Figure 3 Expression of GFP in a first stage Caenorhabdi tis elegans larva. Two touch receptor neurons (PLML and ALML) and one other neuron of unknown function (ALNL) are indicated. Processes can be seen projecting from all three cell bodies. The arrow points to the nerve ring branch from the ALML cell (out of focus). The background fluorescence is due to the animal's autofluorescence.
-WOg5/07463 PCT~S94/10165 _ 21 692 98 Detailed DescriPtion of the Invention Throughout this application, the following standard abbreviations are used to indicate specific nucleotides:
C=cytosine A=adenosine T=thymidine G=guanosine This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein.
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the cell is selected from a group consisting essentially of bacterial cell, yeast cell, fungal cell, insect cell, nematode cell, plant or animal cell.
Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various vertebral, invertebral, m~mm~l ian cells.
In an embodiment, the bacterial cell is Escherichia coli.
As used herein, "a regulatory element" from a gene is the DNA sequence which is necessary for the transcription of the gene.
In this invention, the term ~operatively linked" means that following such a link the regulatory element can WOgS/07463 PCT~S94/10165 69 ~98 - 6 -direct the transcription of the linked protein-coding DNA
~equence.
The gene encoding a green fluorescent protein includes DNA molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms.
These DNA molecules include: the incorporation of codons "preferred" for expression by selected mammalian or non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA
sequences that facilitate construction of expression vectors.
As an example, plasmid pGFPlO.l codes for a mutated GFP
protein having the 80th amino acid residue as an arginine rather than a glutamine predicted to be in native GFP
from A. victoria. This mutated protein retains the property to fluoresce like the natural protein.
In an embodiment, the regulatory element is a promoter.
In a further embodiment, the promoter is activated by a heavy metal. Such promoters are well-known in the art (J.H. Freedman, L.W. Slice, A. Fire, and C.S. Rubin (1993) Journal of Biological Chemistry, 268:2554).
W095/07463 PCT~S94110165 9 ~ 9 ~
In another embodiment, the promoter is that from a cytochrome P450 gene. Cytochrome P450 is well-known in the art and there are a number of P450 promoters known.
.
In still another embodiment, the promoter is that from a stress protein gene. Such stress proteins are well-known in the art (E.G. Stringham, D.K. Dixon, D. Jones and E.D.
Candido (1992) Molecular Biology of the Cell, 3:221; and William J. Welch (May, 1993), Scientific American, page 56). In a further embodiment, the stress protein is a heat-shock protein.
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent.protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the promoter is from a gene necessary for the viability of a cell.
In another embodiment, the regulatory element is an enhancer. Enhancers are well-known in the art.
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the DNA sequence encodes the Aequorea victoria green fluorescent protein.
In an embodiment, the Aequorea victoria green fluorescent protein is cloned in a plasmid. This plasmid is a modification of the pBS(+) (formerly called Bluescribe +) vector (Stratagene~) which has inserted within it an EcoRI fragment containing the cDNA sequence of the Aeq~orea victoria green fluorescent protein ~as modified W095/07463 PCT~S94110165 6q ~9 8 - 8 -herein). The fragment was obtained from ~GFP10 (Prasher, D.C., Eckenrode, V.K., Ward, W.W.; Prendergast, F.G., and Cormier, M.J., (1992) Primary structure of the Aequorea victoria green fluorescent protein. Gene, 111:229-233) by amplification using the polymerase chain reaction (Saiki, R.K., Gelfand, D.H., Stoffèl, S., Sharf, S.J., Higuchi~
G.T., Horn, G.T., Mullis, K.B., and Erlich, H.A. (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239:487-491) with primers flanking the EcoRI sites and subsequent digestion with EcoRI. The sequence of the cDNA in pGFP10.1 differs from the published sequence (5) by a change of the 80th codon of the coding sequence from CAG to CGG, a change that replaces a glutamine with arginine in the protein sequence.
This pGFP10.1 plasmid was deposited on September 1, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. Plasmid pGFP10.1 was accorded ATCC Accession Number 75547.
In another embodiment, this invention provide a bacterial cell which is expressing the green fluorescent protein.
In an further embodiment, the bacterial cell is an E.coli cell. In a still further embodiment, this E.coli cell is designated SMCl (ATCC Accession No. 6g554).
This SMCl bacterial cell was deposited on February 4, 1994, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of WO95/07463 PCT~S94/10165 2 ~ 69298 Microorganism for the Purposes of Patent Procedure.
Bacterial cell SMC1 was accorded ATCC Accession Number 69554.
.
This invention further provides an isolated green fluorescent protein produced from the above-described cells which comprise a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein. This isolated green fluorescent protein can then be further modified in vitro for various uses.
This invention disclose an efficient method for expression of green fluorescent protein such that large amount of the protein could be produced. Methods to isolate expressed protein have been well-known and therefore, green fluorescent protein may be isolated easily.
This invention provides a living organism comprising the cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein.
In another embodiment, the living organism is human. In another embodiment, the living organism is a mouse. The living organism may be other mAmm~ls. In addition, this invention is applicable to other vertebrates, non-vertebrates and living organisms.
In an embodiment, the living organism is C. elegans. In still another embodiment, the living organism is Drosophila, zebra fish, virus or bacteriophage.
.
W095/07463 PCT~S94110165 2.~ 6q~q~ ~) A bacteriophage carrying the green fluorescent protein gene can infect a particular type of bacteria. The infection may be easily detected via the expression of the green fluorescent protein. Therefore, by using appropriate bacteriophages, the presence of that particular type of bacteria may be detected.
., Similarly, a eucaryotic virus carrying the green fluorescent protein gene may infect a specific cell type.
The infection may be easily detected by monitoring the expression of the green fluorescent protein.
Methods to introduce exogenous genetic material into a cell are well-known in the art. For example, exogenous DNA material may be introduced into the cell by calcium phosphate precipitation technology. Other technologies, such as the retroviral vector technology, electroporation, lipofection and other viral vector systems such as adeno-associated virus system, or microinjection may be used.
The above-described cells and living organisms are useful to detect effects of external stimulus to the regulatory element. The stimulus may have direct or indirect effects on the regulatory element. Such effects will be detectable through either the induction of expression and production of the green fluorescent protein or switching off the expression of the green fluorescent protein.
Cells expressing the green fluorescent proteins may be conveniently separated by a fluorescence-activated cell sorter.
These cells and organisms may be used to detect the presence of different molecules in various kinds of Woss/07463 PCT~S94110165 ~ -11- 2169298 biological samples such as blood, urine or saliva. By operatively linking a regulatory element of the gene which is affected by the molecule of interest to a green fluorescent protein, the presence of the molecules will affect the regulatory element which in turn will affect the expression of the green fluorescent protein.
Therefore, the above-described cells are useful for the detection of molecules. Such detection may be used for diagnostic purposes. An example of such a molecule is a hormone.
This invention provides a living organism comprising the cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the regulatory element is for a stress protein.
This invention provides a living organism comprising the cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the stress protein is a heat-shock protein.
This invention provides a method to produce green fluorescent protein comprising a) culturing the above-described cells comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein;
and b) isolating and purifying the green fluorescent protein produced from the cells. Standard methods for isolating and purifying proteins are well-known in the art. In an embodiment, the cells used for production of W095/07463 PCT~S94/10165 6q ~9 ~ - 12 -green fluorescent proteins are E. coli cells. In a further embodiment, the E. coli cells are cultured aerobically.
This invention provides a method to synthesize green fluorescent protein comprising a) culturing tne cell designated SMCl; and b) isolating and purifying the green fluorescent protein produced from the cell.
This invention provides a method for selecting cells expressing a protein of interest which comprises: a) introducing into the cells a DNAI molecule having DNA
sequence encoding the protein of interest and DNAII
molecule having DNA sequence encoding a green fluorescent protein; b) culturing the introduced cells in conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest.
This invention also provides the above method, wherein the cells are selected from a group consisting essentially of bacterial cells, yeast cells, fungal cells, insect cells, nematode cells, plant or animal cells. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various primary m~mm~lian cells.
In an embodiment, DNAI and DNAII are linked. In another embodiment, the DNA encodes the Aequorea victoria green fluorescent protein.
This invention provides a method for localizing a protein of interest in a cell which comprises: a) introducing Wos~/07463 PCT~S~4/10165 into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein; and c) detecting the fused protein composed of the green fluorescent protein in the cell, thereby localizing a protein of interest in a cell.
Regulatory elements required for expression include promoter sequences to bind RNA polymerase and translation initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for translation initiation the Shine-Dalgarno sequence and the start codon ATG.
Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon ATG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art, for example the methods described above for constructing vectors in general.
To maximize the expression of the green fluorescent protein, the sequence flanking the translation initiation codon may be modified (reviewed by Kozak, 1984), compilation and analysis of sequences upstream from the translation start site in eucaryotic mRNAs. Nucl . Acids .
Res. 12:857-872). A sequence may then be generated to produce higher amounts of the GFP protein.
In addition, artificial introns may be introduced so as to increase the production of the protein.
W095/07463 PCT~S94/10165 Z~ 69 ~q ~ - 14 - ~ I
Other special targeting sequences may be inserted into the GFP gene. One such targeting se~uence is the n~clear localization signal (such as the SV40 nuclear localization signal).
The host cell of the above expression system may be selected from the group consisting of the cells where the protein of interest is normally expressed, or foreign cells such as bacterial cells (such as E. coli), yeast cells, fungal cells, insect cells (such as Sf9 celi in the baculovirus expression system), nematode cells, plant or ~n i m~ 1 cells, where the protein of interest is not normally expressed. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various primary m~mm~l ian cells.
In an embodiment of the method for localizing a protein of interest in a cell, the DNA encoding the green fluorescent protein is from Aequorea victoria.
This invention provides a method for localizing a protein of interest in a cell which comprises: a) introducing into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein; and c) detecting the location of the fused protein composed of green fluorescent protein in the cell, thereby localizing a protein of interest in a cell, wherein the cell normally expressing the protein of interest.
This invention provides a method for detecting expression W095/0746~ 2 1 6 9 2 9 8 PCT~Sg4/10165 -of a gene in a cell which comprises: a) introducing into the cell a DNA molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein; b) culturing the cell in conditions permitting expression of the gene; and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
This invention provides a method for indicating expression of a gene in a subject which comprises: a) introducing into a cell of the subject a DNA molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein;
and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
In an embodiment of the above methods, the green fluorescent protein is the Aequorea victoria green fluorescent protein.
This invention provides a method for determining the tissue-specificity of transcription of a DNA sequence in a subject which comprises: a) introducing into a cell of the subject a DNA molecule having the DNA sequence linked to DNA sequence encoding a green fluorescent protein such that the DNA sequence will control expression of the green fluorescent protein; b) culturing the subject in conditions permitting the expression of the green fluorescent protein; and c) detecting the expression of W095/07463 PCT~S94/10165 69 ~9 8 - 16 -the green fluorescent protein in different tissue of thesubject, thereby determining the tissue-specificity of the expression of the DNA sequence.
This invention provides a method for determining the presence of heavy metal in a solution which comprises:
a) culturing the cell comprising a DNA molecule having a promoter from a gene, other than a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein transcription at the promoter is activated by a heavy metal in the solution;
and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of heavy metal.
This invention provides a method for detecting pollutants in a solution which comprises: a) culturing the cell comprising a DNA molecule having a promoter from a gene, other than a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the promoter is activated by a heavy metal or a toxic organic compound or the promoter is for a stress protein in the solution; and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of pollutants in the solution.
Finally, this invention provides a method for producing fluorescent molecular weight markers comprising: a) linking a DNA molecule encoding a green fluorescent protein with a DNA molecule encoding a known amino acid sequence in the same reading frame; b) introducing the linked DNA molecule of step a) in an expression system permitting the expression of a fluorescent protein encoded by the linked DNA molecule; and c) determining WOg5/07463 PCT~S94/10165 the molecular weight of the expressed fluorescent protein of step b), thereby producing a fluorescent molecular weight marker.
Various expression systems are known in the art. The E.
coli expression system, one of the commonly used system is described in the following section.
The determination of molecular weight may be done by comparing the expressed fluorescent protein of step b) with known molecular weight markers. Alternatively, the molecular weight can be predicted by calculation since the linked DNA sequence is known (and so is the amino acid sequence being encoded). In an embodiment, the expressed fluorescent protein is purified. The purified fluorescent protein can be conveniently used as molecular weight markers.
This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
Woss/07463 PCT~S94110165 ~ 69 ~q ~ - - 18 - ~ ' Ex~erimental Detail 8 A cDNA for the Ae~uorea victoria green fluorescent protein (GFP) produces a fluorescent product when expressed in prokaryotic (Escherichia coli) or eukaryotic (Caenorhabditis elegans) cells. Because exogenous substrates and cofactors are not required for this fluorescence, GFP expression can be used to monitor gene expression and protein localization in living organisms.
Light is produced by the bioluminescent jellyfish Aequorea victoria when calcium binds to the photoprotein aequorin (1). Although activation of aequorin in vitro or in heterologous cells produces blue light, the jellyfish produces green light. This latter light is the result of a second protein in A. victoria that derives its excitation energy from aequorin (2), the green fluorescent protein (GFP).
Purified GFP, a protein of 238 amino acids (3), absorbs blue light (maximally at 395 nm with a minor peak at 470 nm) and emits green light (peak emission at 509 nm with a shoulder at 540 nm) (2, 4). This fluorescence is very stable; virtually no photobleaching is observed (5).
Although the intact protein is needed for fluorescence, the same absorption spectral propertles found in the denatured protein are found in a hexapeptide that starts at amino acid 64 (6, 7). The GFP chromophore is derived from the primary amino acid sequence through the cyclization of Ser-dehydroTyr-Gly within this hexapeptide (7). The mechanisms that produce the dehydrotyrosine and cyclize the polypeptide to form the chromophore are unknown. To determine whether additional factors from A.
victoria were needed for the production of the fluorescent protein, applicants tested GFP fluorescence W095/07463 2 1 6 9 ~ q 8 PCT~Ss4/l0l65 .~
in heterologous systems. Here applicants show that GFP
expressed in prokaryotic and eukaryotic cells is capable of producing a strong green fluorescence when exclted by blue light. Because this fluorescence requires no additional gene products from A. victoria, chromophore formation is not species specific and occurs either through the use of ubiquitous cellular components or by autocatalysis.
Expression of GFP in Escherichia coli (8) under the control of the T7 promoter results in a readily detected green fluorescence (9) that is not observed in control bacteria. Upon illumination with a long-wave W source, fluorescent bacteria were detected on agar plates containing the inducer isopropyl-~-D-thiogalactoside (IPTG) (Fig. 1). When GFP was partially purified from this strain (10), it was found to have fluorescence excitation and emission spectra indistinguishable from those of the purified native protein (Fig. 2). The spectral properties of the recombinant GFP suggest that the chromophore can form in the absence of other A.
victoria products.
Transformation of the nematode Caenorhabditis elegans also resulted in the production of fluorescent GFP (11) (Fig. 3). GFP was expressed in a small number of neurons under the control of a promoter for the mec-7 gene. The mec-7 gene encodes a ~-tubulin (12) that is abundant in six touch receptor neurons in C. elegans and less abundant in a few other neurons (13, 14). The pattern of expression of GFP was similar to that detected by MEC-7 antibody or from mec-71acZ fusions (13-15). The strongest fluorescence was seen in the cell bodies of the four embryonically-derived touch receptor neurons (ALML, ALMR, PLML, PLMR) in younger larvae. The processes from W095/07463 PCT~S94tlO165 ~q ~q ~ - 20 -these cells, including their terminal branches, were often visible in larval animals. In some newly hatched animals, the PLM processes were short and ended in what appeared to be prominent growth cones. In older larvae, the cell bodies of the remaining touch cells (AVM and PVM) were also seen; the processes of these cells were more difficult to detect. These postembryonically-derived cells arise during the first of the four larval stages (16), but their outgrowth occurs in the following larval stages (17), with the cells becoming functional during the fourth larval stage (18). GFP's fluorescence in these cells is consistent with these previous results:
no fluorescence was detected in these cells in newly hatched or late first-stage larvae, but it was seen in four of ten late second-stage larvae, all nine early fourth-stage larvae, and seven of eight young adults (l9). In addition, moderate to weak fluorescence was seen in a few other neurons (Fig. 3) (20) . The details of the expression pattern are being ~mi ned.
Like the native protein, GFP expressed in both E. coli and C. elegans is quite stable (lasting at least ten minutes) when illuminated with 450-490 nm light. Some photobleaching occurs, however, when the cells are illuminated with 340-390 nm or 395-440 nm light (21).
Several methods are available to monitor gene activity and protein distribution within cells. These include the formation of fusion proteins with coding sequences for ~-galactosidase, firefly luciferase, and bacterialluciferase (22). Because such methods require exogenously-added substrates or cofactors, they are of limited use with living tissue. Because the detection of intracellular GFP requires only irradiation by near W or blue light, it is not substrate limited. Thus, it should WO95/07463 2 1 6 9 2 9 8 PCT~Sg4/10165 provide an excellent means for monitoring gene expression and protein localization in living cells (23, 24).
Because it does not appear to interfere with cell growth and function, GFP should also be a convenient indicator of transformation and one that could allow cells to be separated using fluorescence-activated cell sorting.
Applicants also envision that GFP can be used as a vital marker so that cell growth (for example, the elaboration of neuronal processes) and movement can be followed in situ, especially in animals that are essentially transparent like C. elegans and zebrafish. The relatively small size of the protein may facilitate its diffusion throughout the cytoplasm of extensively branched cells like neurons and glia. Since the GFP
fluorescence persists after treatment with formaldehyde (9), fixed preparations can also be ~x~m;ned. In addition, absorption of appropriate laser light by GFP-expressing cells (as has been done for lucifer yellow-containing cells) (25), could result in the selective killing of the cells.
Further Experiments on GFP ExPression The TU#58 plasmid, which contains the green fluorescent protein (GFP) coding sequence in the pET3a expression vector (29) was transformed into Escherichia coli strain BLR (DE3) (A. Roca, University of Wisconsin: cited in the Novogen Catalogue) using procedures described previously (29). The resulting strain (SMC3), because of the reduced recombination of the host, was much more stable for GFP expression (all the colonies on plates with ampicillin but without the IPTG inducer (29) were brightly fluorescent when viewed with a hand-held UV
lamp).
W095/07463 PCT~S94/10165 ~ 69 ~9 8 - 22 -A second construct ~TU#147), similar to TU~58, was made with pET11 (A.H. Rosenberg, et al. 1987). Expression in BLR (DE3) from this plasmid was more tightly controlled;
expression was seen soon after IPTG was added, but only after some time without inducer.
The SMC3 strain was used to test the requirement for aerobic growth of the bacteria for the production of a fluorescent product. Plates were grown under anaerobic conditions in a Gas-Pak container according to the instructions of the manufacturer (Becton Dic~inson Microbiology Systems). Colony growth was slowed under anaerobic conditions and the resulting colones were not detectably fluorescent after at least 3 days of growth under anaerobic conditions (using the hand-held W lab).
Colonies, however, became fluorescent after a day's exposure to room air (some fluorescence was seen after a few hours).
PCT~S94/1~165 W095/07463 2 1 6 ~ 2 ~ 8 REFERENCES AND NOTES
1. O. Shimomura, F.H. Johnson, Y. Saiga, J. Cell. Comp.
P~ysiol. 59, 223 (1962).
2. J. G. Morin and J. W. Hastings, J. Cell. Physiol.
77, 313 (1971); H. Morise, O. Shimomura, F. H.
Johnson, J. Winant, Biochemistry 13, 2656 (1974).
3. D. C. Prasher, V. K. Eckenrode, W.W. Ward, F. G.
Prendergast, M. J. Cormier, Gene 111, 229 (1992).
This application is a continuation-in-part of United States Application Serial Nos. 08/119,678 and 08/192,274, filed September 10, 1993 and February 4, 1994, respectively, the contents of which are hereby incorporated by reference.
The invention disclGsed here n was made with Government support under NIH Grant No. 5ROlGM30997 from the Department of Health and Human Services. Accordingly, the U.S. Government has certain rights in this invention.
sac~o~d of the invention Throughout this application various references are referred to within parenthesis. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Full bibliographic citation for these references may be found at the end of this application, preceding the sequence listing and the claims.
Several methods are available to monitor gene activity and protein distribution within cells. These include the formation of fusion proteins with coding sequences for ~-galactosidase (22), and luciferases (22). The usefulness of these methods is often limited by the requirement to fix cell preparations or to add exogenous substrates or cofactors. This invention disclose a method of ex~mining gene expression and protein localizatlon in living cells that requires no exogenously-added compounds.
~ This method uses a cDNA encoding the Green fluorescent W095/07463 PCT~S94/10165 2~ 6~298 2 - ~
Protein (GFP) from the jelly fish Aequorea victoria (3 ) .
In A. victoria, GFP absorbs energy generated by aequori.n upon the stimulation by calcium and emits a green light.
This invention discloses that GFP expressed in prokaryotic and eukaryotic cells is capable of producing a strong green fluorescence when excited with near W or blue light. Since this fluorescence requires no additional gene products from A. victoria, chromophore formation is not species specific.
;: .~
W095/07463 2 1 6 q ~ ~ ~ PCT~S94110165 SummarY of the invention This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein. This invention also provides living organisms comprising the above-described cell.
This invention provides a method for selecting cells expressing a protein of interest which comprises: a) introducing into the cells a DNAI molecule having DNA
sequence encoding the protein of interest and DNAI I
molecule having DNA sequence encoding a green fluorescent protein; b) culturing the introduced cells in conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest.
This invention also provides a method for localizing a protein of interest in a cell: a) introducing into a cell a DNA molecule having DNA sequence encoding the protein 2~ of interest linked to DNA sequence encoding the green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein;
c) detecting the location of the fused protein product, thereby localizing the protein of interest.
f, W095/07463 PCT~S94/10165 ~ 69~q8 4 - ~
Brief Descri~tion of Fiqures Figure 1 Expression of GFP in E. coli. The bacteria on the right side of the figure have the GFP
expression plasmid. This photograph was taken while irradiating the agar plate with a hand-held long-wave W source.
Figure 2 Excitation and Emission Spectra of E. coli-generated GFP (solid lines) and purified A.
victoria GFP (L form; dotted lines).
Figure 3 Expression of GFP in a first stage Caenorhabdi tis elegans larva. Two touch receptor neurons (PLML and ALML) and one other neuron of unknown function (ALNL) are indicated. Processes can be seen projecting from all three cell bodies. The arrow points to the nerve ring branch from the ALML cell (out of focus). The background fluorescence is due to the animal's autofluorescence.
-WOg5/07463 PCT~S94/10165 _ 21 692 98 Detailed DescriPtion of the Invention Throughout this application, the following standard abbreviations are used to indicate specific nucleotides:
C=cytosine A=adenosine T=thymidine G=guanosine This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein.
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the cell is selected from a group consisting essentially of bacterial cell, yeast cell, fungal cell, insect cell, nematode cell, plant or animal cell.
Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various vertebral, invertebral, m~mm~l ian cells.
In an embodiment, the bacterial cell is Escherichia coli.
As used herein, "a regulatory element" from a gene is the DNA sequence which is necessary for the transcription of the gene.
In this invention, the term ~operatively linked" means that following such a link the regulatory element can WOgS/07463 PCT~S94/10165 69 ~98 - 6 -direct the transcription of the linked protein-coding DNA
~equence.
The gene encoding a green fluorescent protein includes DNA molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are replaced by other residues and addition analogs where in one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms.
These DNA molecules include: the incorporation of codons "preferred" for expression by selected mammalian or non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of additional initial, terminal or intermediate DNA
sequences that facilitate construction of expression vectors.
As an example, plasmid pGFPlO.l codes for a mutated GFP
protein having the 80th amino acid residue as an arginine rather than a glutamine predicted to be in native GFP
from A. victoria. This mutated protein retains the property to fluoresce like the natural protein.
In an embodiment, the regulatory element is a promoter.
In a further embodiment, the promoter is activated by a heavy metal. Such promoters are well-known in the art (J.H. Freedman, L.W. Slice, A. Fire, and C.S. Rubin (1993) Journal of Biological Chemistry, 268:2554).
W095/07463 PCT~S94110165 9 ~ 9 ~
In another embodiment, the promoter is that from a cytochrome P450 gene. Cytochrome P450 is well-known in the art and there are a number of P450 promoters known.
.
In still another embodiment, the promoter is that from a stress protein gene. Such stress proteins are well-known in the art (E.G. Stringham, D.K. Dixon, D. Jones and E.D.
Candido (1992) Molecular Biology of the Cell, 3:221; and William J. Welch (May, 1993), Scientific American, page 56). In a further embodiment, the stress protein is a heat-shock protein.
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent.protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the promoter is from a gene necessary for the viability of a cell.
In another embodiment, the regulatory element is an enhancer. Enhancers are well-known in the art.
This invention provides a cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the DNA sequence encodes the Aequorea victoria green fluorescent protein.
In an embodiment, the Aequorea victoria green fluorescent protein is cloned in a plasmid. This plasmid is a modification of the pBS(+) (formerly called Bluescribe +) vector (Stratagene~) which has inserted within it an EcoRI fragment containing the cDNA sequence of the Aeq~orea victoria green fluorescent protein ~as modified W095/07463 PCT~S94110165 6q ~9 8 - 8 -herein). The fragment was obtained from ~GFP10 (Prasher, D.C., Eckenrode, V.K., Ward, W.W.; Prendergast, F.G., and Cormier, M.J., (1992) Primary structure of the Aequorea victoria green fluorescent protein. Gene, 111:229-233) by amplification using the polymerase chain reaction (Saiki, R.K., Gelfand, D.H., Stoffèl, S., Sharf, S.J., Higuchi~
G.T., Horn, G.T., Mullis, K.B., and Erlich, H.A. (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239:487-491) with primers flanking the EcoRI sites and subsequent digestion with EcoRI. The sequence of the cDNA in pGFP10.1 differs from the published sequence (5) by a change of the 80th codon of the coding sequence from CAG to CGG, a change that replaces a glutamine with arginine in the protein sequence.
This pGFP10.1 plasmid was deposited on September 1, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganism for the Purposes of Patent Procedure. Plasmid pGFP10.1 was accorded ATCC Accession Number 75547.
In another embodiment, this invention provide a bacterial cell which is expressing the green fluorescent protein.
In an further embodiment, the bacterial cell is an E.coli cell. In a still further embodiment, this E.coli cell is designated SMCl (ATCC Accession No. 6g554).
This SMCl bacterial cell was deposited on February 4, 1994, 1993 with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of WO95/07463 PCT~S94/10165 2 ~ 69298 Microorganism for the Purposes of Patent Procedure.
Bacterial cell SMC1 was accorded ATCC Accession Number 69554.
.
This invention further provides an isolated green fluorescent protein produced from the above-described cells which comprise a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein. This isolated green fluorescent protein can then be further modified in vitro for various uses.
This invention disclose an efficient method for expression of green fluorescent protein such that large amount of the protein could be produced. Methods to isolate expressed protein have been well-known and therefore, green fluorescent protein may be isolated easily.
This invention provides a living organism comprising the cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein.
In another embodiment, the living organism is human. In another embodiment, the living organism is a mouse. The living organism may be other mAmm~ls. In addition, this invention is applicable to other vertebrates, non-vertebrates and living organisms.
In an embodiment, the living organism is C. elegans. In still another embodiment, the living organism is Drosophila, zebra fish, virus or bacteriophage.
.
W095/07463 PCT~S94110165 2.~ 6q~q~ ~) A bacteriophage carrying the green fluorescent protein gene can infect a particular type of bacteria. The infection may be easily detected via the expression of the green fluorescent protein. Therefore, by using appropriate bacteriophages, the presence of that particular type of bacteria may be detected.
., Similarly, a eucaryotic virus carrying the green fluorescent protein gene may infect a specific cell type.
The infection may be easily detected by monitoring the expression of the green fluorescent protein.
Methods to introduce exogenous genetic material into a cell are well-known in the art. For example, exogenous DNA material may be introduced into the cell by calcium phosphate precipitation technology. Other technologies, such as the retroviral vector technology, electroporation, lipofection and other viral vector systems such as adeno-associated virus system, or microinjection may be used.
The above-described cells and living organisms are useful to detect effects of external stimulus to the regulatory element. The stimulus may have direct or indirect effects on the regulatory element. Such effects will be detectable through either the induction of expression and production of the green fluorescent protein or switching off the expression of the green fluorescent protein.
Cells expressing the green fluorescent proteins may be conveniently separated by a fluorescence-activated cell sorter.
These cells and organisms may be used to detect the presence of different molecules in various kinds of Woss/07463 PCT~S94110165 ~ -11- 2169298 biological samples such as blood, urine or saliva. By operatively linking a regulatory element of the gene which is affected by the molecule of interest to a green fluorescent protein, the presence of the molecules will affect the regulatory element which in turn will affect the expression of the green fluorescent protein.
Therefore, the above-described cells are useful for the detection of molecules. Such detection may be used for diagnostic purposes. An example of such a molecule is a hormone.
This invention provides a living organism comprising the cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the regulatory element is for a stress protein.
This invention provides a living organism comprising the cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the stress protein is a heat-shock protein.
This invention provides a method to produce green fluorescent protein comprising a) culturing the above-described cells comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein;
and b) isolating and purifying the green fluorescent protein produced from the cells. Standard methods for isolating and purifying proteins are well-known in the art. In an embodiment, the cells used for production of W095/07463 PCT~S94/10165 6q ~9 ~ - 12 -green fluorescent proteins are E. coli cells. In a further embodiment, the E. coli cells are cultured aerobically.
This invention provides a method to synthesize green fluorescent protein comprising a) culturing tne cell designated SMCl; and b) isolating and purifying the green fluorescent protein produced from the cell.
This invention provides a method for selecting cells expressing a protein of interest which comprises: a) introducing into the cells a DNAI molecule having DNA
sequence encoding the protein of interest and DNAII
molecule having DNA sequence encoding a green fluorescent protein; b) culturing the introduced cells in conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest.
This invention also provides the above method, wherein the cells are selected from a group consisting essentially of bacterial cells, yeast cells, fungal cells, insect cells, nematode cells, plant or animal cells. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various primary m~mm~lian cells.
In an embodiment, DNAI and DNAII are linked. In another embodiment, the DNA encodes the Aequorea victoria green fluorescent protein.
This invention provides a method for localizing a protein of interest in a cell which comprises: a) introducing Wos~/07463 PCT~S~4/10165 into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein; and c) detecting the fused protein composed of the green fluorescent protein in the cell, thereby localizing a protein of interest in a cell.
Regulatory elements required for expression include promoter sequences to bind RNA polymerase and translation initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for translation initiation the Shine-Dalgarno sequence and the start codon ATG.
Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon ATG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art, for example the methods described above for constructing vectors in general.
To maximize the expression of the green fluorescent protein, the sequence flanking the translation initiation codon may be modified (reviewed by Kozak, 1984), compilation and analysis of sequences upstream from the translation start site in eucaryotic mRNAs. Nucl . Acids .
Res. 12:857-872). A sequence may then be generated to produce higher amounts of the GFP protein.
In addition, artificial introns may be introduced so as to increase the production of the protein.
W095/07463 PCT~S94/10165 Z~ 69 ~q ~ - 14 - ~ I
Other special targeting sequences may be inserted into the GFP gene. One such targeting se~uence is the n~clear localization signal (such as the SV40 nuclear localization signal).
The host cell of the above expression system may be selected from the group consisting of the cells where the protein of interest is normally expressed, or foreign cells such as bacterial cells (such as E. coli), yeast cells, fungal cells, insect cells (such as Sf9 celi in the baculovirus expression system), nematode cells, plant or ~n i m~ 1 cells, where the protein of interest is not normally expressed. Suitable animal cells include, but are not limited to Vero cells, HeLa cells, Cos cells, CVl cells and various primary m~mm~l ian cells.
In an embodiment of the method for localizing a protein of interest in a cell, the DNA encoding the green fluorescent protein is from Aequorea victoria.
This invention provides a method for localizing a protein of interest in a cell which comprises: a) introducing into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein; and c) detecting the location of the fused protein composed of green fluorescent protein in the cell, thereby localizing a protein of interest in a cell, wherein the cell normally expressing the protein of interest.
This invention provides a method for detecting expression W095/0746~ 2 1 6 9 2 9 8 PCT~Sg4/10165 -of a gene in a cell which comprises: a) introducing into the cell a DNA molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein; b) culturing the cell in conditions permitting expression of the gene; and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
This invention provides a method for indicating expression of a gene in a subject which comprises: a) introducing into a cell of the subject a DNA molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein; b) culturing the cell in conditions permitting expression of the fused protein;
and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
In an embodiment of the above methods, the green fluorescent protein is the Aequorea victoria green fluorescent protein.
This invention provides a method for determining the tissue-specificity of transcription of a DNA sequence in a subject which comprises: a) introducing into a cell of the subject a DNA molecule having the DNA sequence linked to DNA sequence encoding a green fluorescent protein such that the DNA sequence will control expression of the green fluorescent protein; b) culturing the subject in conditions permitting the expression of the green fluorescent protein; and c) detecting the expression of W095/07463 PCT~S94/10165 69 ~9 8 - 16 -the green fluorescent protein in different tissue of thesubject, thereby determining the tissue-specificity of the expression of the DNA sequence.
This invention provides a method for determining the presence of heavy metal in a solution which comprises:
a) culturing the cell comprising a DNA molecule having a promoter from a gene, other than a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein transcription at the promoter is activated by a heavy metal in the solution;
and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of heavy metal.
This invention provides a method for detecting pollutants in a solution which comprises: a) culturing the cell comprising a DNA molecule having a promoter from a gene, other than a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein, wherein the promoter is activated by a heavy metal or a toxic organic compound or the promoter is for a stress protein in the solution; and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of pollutants in the solution.
Finally, this invention provides a method for producing fluorescent molecular weight markers comprising: a) linking a DNA molecule encoding a green fluorescent protein with a DNA molecule encoding a known amino acid sequence in the same reading frame; b) introducing the linked DNA molecule of step a) in an expression system permitting the expression of a fluorescent protein encoded by the linked DNA molecule; and c) determining WOg5/07463 PCT~S94/10165 the molecular weight of the expressed fluorescent protein of step b), thereby producing a fluorescent molecular weight marker.
Various expression systems are known in the art. The E.
coli expression system, one of the commonly used system is described in the following section.
The determination of molecular weight may be done by comparing the expressed fluorescent protein of step b) with known molecular weight markers. Alternatively, the molecular weight can be predicted by calculation since the linked DNA sequence is known (and so is the amino acid sequence being encoded). In an embodiment, the expressed fluorescent protein is purified. The purified fluorescent protein can be conveniently used as molecular weight markers.
This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.
Woss/07463 PCT~S94110165 ~ 69 ~q ~ - - 18 - ~ ' Ex~erimental Detail 8 A cDNA for the Ae~uorea victoria green fluorescent protein (GFP) produces a fluorescent product when expressed in prokaryotic (Escherichia coli) or eukaryotic (Caenorhabditis elegans) cells. Because exogenous substrates and cofactors are not required for this fluorescence, GFP expression can be used to monitor gene expression and protein localization in living organisms.
Light is produced by the bioluminescent jellyfish Aequorea victoria when calcium binds to the photoprotein aequorin (1). Although activation of aequorin in vitro or in heterologous cells produces blue light, the jellyfish produces green light. This latter light is the result of a second protein in A. victoria that derives its excitation energy from aequorin (2), the green fluorescent protein (GFP).
Purified GFP, a protein of 238 amino acids (3), absorbs blue light (maximally at 395 nm with a minor peak at 470 nm) and emits green light (peak emission at 509 nm with a shoulder at 540 nm) (2, 4). This fluorescence is very stable; virtually no photobleaching is observed (5).
Although the intact protein is needed for fluorescence, the same absorption spectral propertles found in the denatured protein are found in a hexapeptide that starts at amino acid 64 (6, 7). The GFP chromophore is derived from the primary amino acid sequence through the cyclization of Ser-dehydroTyr-Gly within this hexapeptide (7). The mechanisms that produce the dehydrotyrosine and cyclize the polypeptide to form the chromophore are unknown. To determine whether additional factors from A.
victoria were needed for the production of the fluorescent protein, applicants tested GFP fluorescence W095/07463 2 1 6 9 ~ q 8 PCT~Ss4/l0l65 .~
in heterologous systems. Here applicants show that GFP
expressed in prokaryotic and eukaryotic cells is capable of producing a strong green fluorescence when exclted by blue light. Because this fluorescence requires no additional gene products from A. victoria, chromophore formation is not species specific and occurs either through the use of ubiquitous cellular components or by autocatalysis.
Expression of GFP in Escherichia coli (8) under the control of the T7 promoter results in a readily detected green fluorescence (9) that is not observed in control bacteria. Upon illumination with a long-wave W source, fluorescent bacteria were detected on agar plates containing the inducer isopropyl-~-D-thiogalactoside (IPTG) (Fig. 1). When GFP was partially purified from this strain (10), it was found to have fluorescence excitation and emission spectra indistinguishable from those of the purified native protein (Fig. 2). The spectral properties of the recombinant GFP suggest that the chromophore can form in the absence of other A.
victoria products.
Transformation of the nematode Caenorhabditis elegans also resulted in the production of fluorescent GFP (11) (Fig. 3). GFP was expressed in a small number of neurons under the control of a promoter for the mec-7 gene. The mec-7 gene encodes a ~-tubulin (12) that is abundant in six touch receptor neurons in C. elegans and less abundant in a few other neurons (13, 14). The pattern of expression of GFP was similar to that detected by MEC-7 antibody or from mec-71acZ fusions (13-15). The strongest fluorescence was seen in the cell bodies of the four embryonically-derived touch receptor neurons (ALML, ALMR, PLML, PLMR) in younger larvae. The processes from W095/07463 PCT~S94tlO165 ~q ~q ~ - 20 -these cells, including their terminal branches, were often visible in larval animals. In some newly hatched animals, the PLM processes were short and ended in what appeared to be prominent growth cones. In older larvae, the cell bodies of the remaining touch cells (AVM and PVM) were also seen; the processes of these cells were more difficult to detect. These postembryonically-derived cells arise during the first of the four larval stages (16), but their outgrowth occurs in the following larval stages (17), with the cells becoming functional during the fourth larval stage (18). GFP's fluorescence in these cells is consistent with these previous results:
no fluorescence was detected in these cells in newly hatched or late first-stage larvae, but it was seen in four of ten late second-stage larvae, all nine early fourth-stage larvae, and seven of eight young adults (l9). In addition, moderate to weak fluorescence was seen in a few other neurons (Fig. 3) (20) . The details of the expression pattern are being ~mi ned.
Like the native protein, GFP expressed in both E. coli and C. elegans is quite stable (lasting at least ten minutes) when illuminated with 450-490 nm light. Some photobleaching occurs, however, when the cells are illuminated with 340-390 nm or 395-440 nm light (21).
Several methods are available to monitor gene activity and protein distribution within cells. These include the formation of fusion proteins with coding sequences for ~-galactosidase, firefly luciferase, and bacterialluciferase (22). Because such methods require exogenously-added substrates or cofactors, they are of limited use with living tissue. Because the detection of intracellular GFP requires only irradiation by near W or blue light, it is not substrate limited. Thus, it should WO95/07463 2 1 6 9 2 9 8 PCT~Sg4/10165 provide an excellent means for monitoring gene expression and protein localization in living cells (23, 24).
Because it does not appear to interfere with cell growth and function, GFP should also be a convenient indicator of transformation and one that could allow cells to be separated using fluorescence-activated cell sorting.
Applicants also envision that GFP can be used as a vital marker so that cell growth (for example, the elaboration of neuronal processes) and movement can be followed in situ, especially in animals that are essentially transparent like C. elegans and zebrafish. The relatively small size of the protein may facilitate its diffusion throughout the cytoplasm of extensively branched cells like neurons and glia. Since the GFP
fluorescence persists after treatment with formaldehyde (9), fixed preparations can also be ~x~m;ned. In addition, absorption of appropriate laser light by GFP-expressing cells (as has been done for lucifer yellow-containing cells) (25), could result in the selective killing of the cells.
Further Experiments on GFP ExPression The TU#58 plasmid, which contains the green fluorescent protein (GFP) coding sequence in the pET3a expression vector (29) was transformed into Escherichia coli strain BLR (DE3) (A. Roca, University of Wisconsin: cited in the Novogen Catalogue) using procedures described previously (29). The resulting strain (SMC3), because of the reduced recombination of the host, was much more stable for GFP expression (all the colonies on plates with ampicillin but without the IPTG inducer (29) were brightly fluorescent when viewed with a hand-held UV
lamp).
W095/07463 PCT~S94/10165 ~ 69 ~9 8 - 22 -A second construct ~TU#147), similar to TU~58, was made with pET11 (A.H. Rosenberg, et al. 1987). Expression in BLR (DE3) from this plasmid was more tightly controlled;
expression was seen soon after IPTG was added, but only after some time without inducer.
The SMC3 strain was used to test the requirement for aerobic growth of the bacteria for the production of a fluorescent product. Plates were grown under anaerobic conditions in a Gas-Pak container according to the instructions of the manufacturer (Becton Dic~inson Microbiology Systems). Colony growth was slowed under anaerobic conditions and the resulting colones were not detectably fluorescent after at least 3 days of growth under anaerobic conditions (using the hand-held W lab).
Colonies, however, became fluorescent after a day's exposure to room air (some fluorescence was seen after a few hours).
PCT~S94/1~165 W095/07463 2 1 6 ~ 2 ~ 8 REFERENCES AND NOTES
1. O. Shimomura, F.H. Johnson, Y. Saiga, J. Cell. Comp.
P~ysiol. 59, 223 (1962).
2. J. G. Morin and J. W. Hastings, J. Cell. Physiol.
77, 313 (1971); H. Morise, O. Shimomura, F. H.
Johnson, J. Winant, Biochemistry 13, 2656 (1974).
3. D. C. Prasher, V. K. Eckenrode, W.W. Ward, F. G.
Prendergast, M. J. Cormier, Gene 111, 229 (1992).
4. W. W. Ward, C. W. Cody, R. C. Hart, M. J. Cormier, Photochem. Photobiol. 31, 611 (1980).
5. F. G. Prendergast, personal communication.
6. O. Shimomura, FEBS Lett. 104, 220 (1979).
7. C. W. Cody, D. C. Prasher, W. M. Westler, F. G.
Prendergast, W. W. Ward, Biochemistry 32, 1212 (1993).
Prendergast, W. W. Ward, Biochemistry 32, 1212 (1993).
8. Plasmid pGFP10.1 contains the EcoRI fragment encoding the GFP cDNA from AgfplO (3) in pBS(+) (Stratagene~). The fragment was obtained by amplification with the polymerase chain reaction [PCR; R. K. Saiki et al., Science 239, 487 (1988)~
with primers flanking the EcoRI sites and subsequent digestion with EcoRI. DNA was prepared by the Magic Minipreps procedure (Promega) and sequenced (after an additional ethanol precipitation) on an Applied Biosystems DNA Sequencer 370A at the DNA Sequencing facility at Columbia College of Physicians and Surgeons. The sequence of the cDNA in pGFP10.1 PCT~S94/10165 6q ~q 8 - 24 -differs from the published sequence by a change in codon 80 within the coding sequence from CAG to CGG, a change that replaces a glutamine residue with arginine [R. Heim, S. Emr, and R. Tsien (personal communication) first alerted us to a possible se~uence change in this clone and independently noted the same change.] This replacement has no detectable effect on the spectral properties of the protein (Fig. 2).
An E. coli expression construct was made with PCR to generate a fragment with an NheI site at the start of translation and an EcoRI site 5' to the termination signal of the GFP coding sequence from pGFP10.1. The 5' primer was ACAAAGGCTAGCAAAGGAGAAGAAC (Sequence ID No. 1) and the 3' primer was the T3 primer (Stratagene~). The NheI-EcoRI fragment was ligated into the similarly cut vector pET3a [A.H. Rosenberg e t al ., Gene 5 6 , 125 (1987)] by standard methods (26). The resulting coding sequence substitutes an Ala for the initial GFP Met, which becomes the second amino acid in the polypeptide. The E. coli strain BL21(DE3)Lys S [F.
W. Studier and B. A. Moffat, J. Mol. Biol. 189, 113 (1986)] was transformed with the resulting plasmid (TU#58) and grown at 37C. Control bacteria were transformed with pET3a. Bacteria were grown on nutrient plates containing ampicillin (100 ~g/ml) and 0.8 mM IPTG. Transformed bacteria from this transformation show green fluorescence when irradiated with ultraviolet light. A recombinant plasmid of this bacteria was used for the experiments described here and the experiment in Figure 2 and the experiment in Note 10. Several months later, applicants noticed that the bacterial PCT~S~4/10165 wos5lo7463 ~ _252-l692~8 colonies can be divided into two groups: l) strongly fluorescent; and 2) weakly fluorescent (applicants believe that the weakly fluorescent may have mutated, disabled or partial or completely deleted TU#58). One strongly fluorescent colony was picked to generate the bacterial strain SMCl (ATCC
Accession No. 69554). [A similar PCR-generated fragment (see note 11) was used in applicants' C.
el egans construct. As others are beginning to use pGFPl0.l, applicants have heard that while similar PCR fragments produce a fluorescent product in other organisms (R. Heim, S. Emr, and R. Tsien, personal communication; S. Wang and T. Hazelrigg, personal communication; L. T ~n n and F. McKeon, personal communication; see note 23), the EcoRI fragment does not (R. Heim, S. Emr, and R. Tsien, personal communication; A. Coxon, J. R. Chaillet, and T.
Bestor, personal communication). These results may indicate that elements at the 5' end of the sequence or at the start of translation inhibit expression.]
with primers flanking the EcoRI sites and subsequent digestion with EcoRI. DNA was prepared by the Magic Minipreps procedure (Promega) and sequenced (after an additional ethanol precipitation) on an Applied Biosystems DNA Sequencer 370A at the DNA Sequencing facility at Columbia College of Physicians and Surgeons. The sequence of the cDNA in pGFP10.1 PCT~S94/10165 6q ~q 8 - 24 -differs from the published sequence by a change in codon 80 within the coding sequence from CAG to CGG, a change that replaces a glutamine residue with arginine [R. Heim, S. Emr, and R. Tsien (personal communication) first alerted us to a possible se~uence change in this clone and independently noted the same change.] This replacement has no detectable effect on the spectral properties of the protein (Fig. 2).
An E. coli expression construct was made with PCR to generate a fragment with an NheI site at the start of translation and an EcoRI site 5' to the termination signal of the GFP coding sequence from pGFP10.1. The 5' primer was ACAAAGGCTAGCAAAGGAGAAGAAC (Sequence ID No. 1) and the 3' primer was the T3 primer (Stratagene~). The NheI-EcoRI fragment was ligated into the similarly cut vector pET3a [A.H. Rosenberg e t al ., Gene 5 6 , 125 (1987)] by standard methods (26). The resulting coding sequence substitutes an Ala for the initial GFP Met, which becomes the second amino acid in the polypeptide. The E. coli strain BL21(DE3)Lys S [F.
W. Studier and B. A. Moffat, J. Mol. Biol. 189, 113 (1986)] was transformed with the resulting plasmid (TU#58) and grown at 37C. Control bacteria were transformed with pET3a. Bacteria were grown on nutrient plates containing ampicillin (100 ~g/ml) and 0.8 mM IPTG. Transformed bacteria from this transformation show green fluorescence when irradiated with ultraviolet light. A recombinant plasmid of this bacteria was used for the experiments described here and the experiment in Figure 2 and the experiment in Note 10. Several months later, applicants noticed that the bacterial PCT~S~4/10165 wos5lo7463 ~ _252-l692~8 colonies can be divided into two groups: l) strongly fluorescent; and 2) weakly fluorescent (applicants believe that the weakly fluorescent may have mutated, disabled or partial or completely deleted TU#58). One strongly fluorescent colony was picked to generate the bacterial strain SMCl (ATCC
Accession No. 69554). [A similar PCR-generated fragment (see note 11) was used in applicants' C.
el egans construct. As others are beginning to use pGFPl0.l, applicants have heard that while similar PCR fragments produce a fluorescent product in other organisms (R. Heim, S. Emr, and R. Tsien, personal communication; S. Wang and T. Hazelrigg, personal communication; L. T ~n n and F. McKeon, personal communication; see note 23), the EcoRI fragment does not (R. Heim, S. Emr, and R. Tsien, personal communication; A. Coxon, J. R. Chaillet, and T.
Bestor, personal communication). These results may indicate that elements at the 5' end of the sequence or at the start of translation inhibit expression.]
9. Applicants used a variety of microscopes (Zeiss Axiophot, Nikon Microphot FXA, and Olympus BH2-RFC
and BX50) equipped for epifluorescence microscopy.
Usually filter sets for fluorescein isothiocyanate fluorescence were used (for example, the Zeiss filter set used a BP450-490 excitation filter, 510 nm dichroic, and either a BP515-565 or a LP520 emission filter), although for some experiments filter sets that excited at lower wavelengths were used (for example, a Zeiss filter set with BP395-440 and LP470 filters and a 460 nm dichroic or with BP340-390 and LP400 filters with a 395 nm dichroic).
In some instances a xenon lamp appeared to give a more intense fluorescence than a mercury lamp when --WOsS/07463 PCT~S94110165 ~q ~9 a - 26 -cells were illuminated with light around 470 nm, although usually the results were comparable. No other attempts were made to enhance the signal (for example, by using low intensity light cameras) although this may be useful in some instances.
Previous experiments had shown that the native protein was fluorescent after glutaraldehyde fixation (W. W. Ward, unpub. data). S. Wang and T.
Hazelrigg (personal communicationi 23) have found that GFP fusion proteins in Drosophila melanogaster are fluorescent after formaldehyde fixation.
Applicants have confirmed that fluorescence persists after formaldehyde fixation with applicants' C.
elegans ~n i m~ 1 S and with recombinant GFP isolated from E. coli. The chemicals in nail polish, which is often used to seal cover slips, however, did appear to interfere with the C. elegans GFP
fluorescence.
lO. In the applicants' initial experiments, GFP was purified from 250 ml cultures of BL21(DE3)Lys S
bacteria containing TU#58; bacteria were grown in LB
broth (26) containing ampicillin (lO0 ~g/ml) and 0.8 mM IPTG. Induction was best when IPTG was present continually. Nevertheless, subsequent experiments with bacterial strain SMCl indicate that the bacteria could not grow in the constant presence of IPTG but can be induced by the IPTG during the log phase growth. The production of fluorescent protein is best at room temperature. Cells were washed in 4 ml of lO mM Tris-HCl (pH 7.4), lO0 mM NaCl, l mM
MgCl2, and lO mM dithiothreitol [A. Kumagai and W.
G. Dunphy, Cell 64, 903 (l99l)] and then sonicated (2 X 20 sec) in 4 ml of the same buffer containing WO95/07463 PCT~S94/10165 ~ - 27 - 2 1 6 9298 0.1 mM PMSF, pepstatin A (1 ~g/ml), leupeptin (1 ~g/ml), and aprotinin (2 ~g/ml), and centrifuged at 5,000 rpm for 5 min in the cold. The supernatant was centrifuged a second time (15,000 rpm for 15 min) and then diluted sevenfold with 10 mM Tris (pH
8.0), 10 mM EDTA, and 0.02~ NaN3. Corrected excitation and emission spectra were obtained with a SPEX FlT11 spectrofluorometer and compared with the purified L isoprotein form of GFP from A.
victoria (M. Cutler, A. Roth, and W. W. Ward, unpub.
data). The excitation spectra were measured from 300 - 500 nm with a fixed emission wavelength of 509 nm, and the emission spectra were measured from 410 - 600 nm with a fixed excitation of 395 nm. All spectra were recorded as signal-reference data (where the reference is a direct measurement of the lamp intensity with a separate photomultiplier tube) at room temperature with 1 ~ec integration times and 1 nm ir.crements. The spectral band widths were adjusted to 0.94 nm for all spectra.
11. Wild-type and mutant C. elegans animals were grown and genetic strains were constructed according to S.
Brenner, Genetics 77, 71 (1974).
The plasmid pGFP10.1 was used as a template for PCR
(with the 5' primer GAATAAAAGCTAGCAAAGATGAGTAAAG
(Sequence ID No. 2) and the 3' T3 primer) to generate a fragment with a 5' NheI site (at the start of translation) and a 3' EcoRI site (3' of the termination codon). The DNA was cut to produce an NheI - EcoRI fragment that was ligated into plasmid pPD 16.51 ( 12, 27), a vector containing the promoter of the C. elegans mec- 7 gene. Wild-type C. elegans were transformed by coinjecting this DNA (TU~64) and PCT~S94110165 w095/07463 ~9 ~ 28 -the DNA for plasmid pRF4, which contains the dominant rol-6 (sulOo6) mutation, into adult C.
elegans gonads as described by C. M. Mello, J. M.
Kramer, D. Stinchcomb, and V. Ambros, EMBO J. 10, 3959 (1991). A relatively stable line was isolated (TU1710) and the DNA it carried was integrated as described by Mitani et al . ( 15) to produce the integrated elements uIs3 and uIs4 (in strains TU1754 and TU1755, respectively).
Living C. elegans animals were mounted on agar (or agarose) pads as described (16), often with 10 mM
NaN3 as an anesthetic (28) (another nematode anesthetic, phenoxypropanol, quenched the fluorescence) and e~m;ned with either a Zeiss universal or axiophot microscope. For C. elegans, a long-pass emission filter works best because the animal's intestinal autofluorescence, (which increases as the animal matures), appears yellow (with band-pass filters the autofluorescence appears green and obscures the GFP fluorescence).
Because much more intense fluorescence was seen in uIs4 than uIs3 animals (for example, it was often difficult to see the processes of the ALM and PLM
cells in uIs3 animals when the animals were illuminated with a mercury lamp), the former have been used for the observations reported here. The general pattern of cell body fluorescence was the same in both strains and in the parental, nonintegrated strain (fluorescence in this strain was as strong as that in the uIs4 animals). The uIs4 animals, however, did show an unusual phenotype: both the ALM and PLM touch cells were often displaced anteriorly. The mature cells PCT~S94/10165 2 ~ 6~29~
usually had processes in the correct positions, although occasional cells had abnormally-projecting processes. These cells could be identified as touch receptor cells, because the fluorescence was dependent on mec-3, a homeobox gene that specifies touch cell fate (13, 15, 18, 28). mec-7 expression is reduced in the ALM touch cells of the head (but not as dramatically in the PLM touch cells of the tail) in mec-3 gene mutants ( 13, 1~) . Applicants find a similar change of GFP expression in a mec-3 mutant background for both uIs3 and uIs4. Thus, GFP
accurately represents the expression pattern of the mec- 7 gene. It is likely that the reduced staining in uIs3 ~nlm~l S and the misplaced cells in uIs4 animals is the result of either secondary mutations or the amount and position of the integrated DNA.
12. C. Savage, M. Hamelin, J. G. Culotti, A. Coulson, D.
G. Albertson, M. Chalfie, Genes Dev. 3, 870 (1989).
13. M. Hamelin, I. M. Scott, J. C. Way, J. G. Culotti, EMBO J. 11, 2885 (1992).
14. A. Duggan and M. Chalfie, unpub. data.
15. S. Mitani, H. P. Du, D. H. Hall, M. Driscoll, M.
Chalfie, Development 119, 773 (1993).
16. J. E. Sulston and H. R. Horvitz, Develop. Biol. 56, 110 (1977).
17. W. W. Walthall and M. Chalfie, Science 239, 643 (1988).
18. M. Chalfie and J. Sulston, Dev. Biol. 82, 358 W095/07463 PCT~S94/1016S
~9 ~q ~ - 30 -(1981).
19. In adults, the thicker size of the animals and the more intense autofluorescence of the intestine tend to obscure these cells.
20. These include several cells in the head (including the FLP cells) and tail~of newly hatched animals and the BDU cells, a pair of neurons just posterior to the pharynx. Expression of mec- 7 in these cells has been seen previously ( 13, 15) . The strongest staining of these non-touch receptor neurons are a pair of cells in the tail that have anteriorly directed processes that project along the dorsal muscle line. It is likely that these are the ALN
cells, the sister cells to the PLM touch cells [J.
G. White, E. Southgate, J. N. Thomson, and S.
Brenner, Philos. Trans. R. Soc. Lond. B Biol. Sci.
314, 1 (1986).]
21. The photobleaching with 395-440 nm light is further accelerated, to within seconds, in the presence of 10 mM NaN3, which is used as a C. elegans anesthetic (11). However, when cells in C. elegans have been photobleached, some recovery is seen within 10 min.
Further investigation is needed to determine whether this recovery represents de novo synthesis of GFP.
Rapid photobleaching (complete within a minute) of the green product was also seen when C. elegans was illuminated with 340-390 nm light. Unlike the photobleaching with 395-440 nm light, which abolished fluorescence produced by the 340-390 or 450-490 nm light, photobleaching with 340-390 nm light did not appear to affect the fluorescence produced by 395-490 or 450-490 nm light. Indeed, W095/07463 2 t 6 92 98 ~CT~S94/10l65 the fluorescence produced by 450-490 nm light appeared to be more intense after brief photobleaching by 340-390 nm light. This selective - photobleaching may indicate the production of more than one fluorescent product in the animal. These data on GFP fluorescence within E. coli and C.
elegans is in contrast to preliminary studies that suggest that the isolated native and E. coli proteins are very photostable. Applicants do not know whether this in vivo sensitivity to photobleaching is a normal feature of ~he jellyfish protein (the fluorescence in A. victoria has not been ~X~m; ned) or results from the absence of a necessary posttranslational modification unique to A. victoria or nonspecific damage within the cells.
22. Reviewed in T. J. Silhavy and ~. R. Beckwith, Microbiol. Rev. 49, 398 (1985); S. J. Gould and S.
Subramani, Anal. Biochem. 175, 5 (1988); and G. S.
A. B. Stewart and P. Williams, J. Gen. Microbiol.
138, 1289 (1992).
23. R. Heim, S. Emr, and R. Tsien (personal communication) have found that GFP expression in Saccharomyces cerevisiae can make the cells strongly fluorescent without causing toxicity. S. Wang and T. Hazelrigg (personal communication) have found that both C-terminal and N-terminal protein fusions with GFP are fluorescent in Drosophila melanogaster.
L. T ~n n 1 and F. McKeon (personal communication) have expressed a GFP protein fusion in m~mm~l ian (COS) cells. E. Macagno (personal communication) is expressing GFP in leeches. T. Hughes (personal communication) is expressing GFP in m~mm~l ian HEK293 cells.
PCT~S94/1016 ~6q~q8 - 32 -24. Applicants have generated several other plasmid constructions that may be useful to investigators.
These include a pBluescript II KS (+) derivative (TU#65) containing a KpnI - EcoRI fragment encoding GFP with an AgeI site 5' to the translation start and a BsmI site at the termination codon. Also available are gfp versions (TU#60 - TU#63) of the four C. elegans lacZ expression vectors (pPD16.43, pPD21.28, pPD22.04, and pPD22.11, respectively) described by Fire et al., 1990 (27) except that they lack the KpnI fragment containing the SV40 nuclear localization signal.
25. J. P. Miller and A. Selverston, Science 206, 702 (1979).
26. J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular cloning: A laboratory manual, 2nd Ed. Cold Spring Harbor Laboratcry Press, Cold Spring Harbor, New York, (1989).
27. A. Fire, S. W. Harrison, and D. Dixon, Gene 93, 189 (1990) .
28. J. C. Way and M. Chalfie, Cell 54, 5 (1988).
29. Chalfie, M., Tu. Y., Euskirchen, G., Ward, W.W., Prasher, D.C., Science 263, 8 02 (1994).
W 095/07463 2 1 6 ~ 2 9 8 PCT~US94/10165 SEQUENCE LIsTING
(1) GENERAL INFORMATION:
(i) APPLICANT: The Trustees of Columbia University in the City of New York and Woods Hole Oceanographic Institute (ii) TITLE OF INVENTION: USES OF GREEN FLUORESCENT PROTEIN
< 10 (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Cooper & Dunham (B) STREET: 30 Rockefeller Plaza (C) CITY: New York (D) STATE: New York (E) COUN1~Y: United States of America (F) ZIP: 10112 (v).COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version ~1.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
~viii) A~llOkN~Y/AGENT INFORMATION:
(A) NAME: White, John P.
(B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 0575/43557-B-PCT
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (212) 977-9550 (B) TELEFAX: (212) 664-0525 (C) TELEX: 422523 COOP UI
(2) INFORMATION FOR SEQ ID NO:l:
(i) S~:Qu~N~ CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: 'inear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Escherichia coli (~i ) S~QU~N~ DESCRIPTION: SEQ ID NO:I:
ACAAAGGCTA GCA~AGGAGA AGAAC 25 W O9S/07463 PCTrUS94/10165 ~ ~ 6 9 ~ q ~ - 34 -(2) INFORMATION FOR SEQ ID NO:2:
(i) S~Q~:NL~: CHARACTERISTICS:
(A) LENGT~. 28 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~nN~s single ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Escherichia coli (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
and BX50) equipped for epifluorescence microscopy.
Usually filter sets for fluorescein isothiocyanate fluorescence were used (for example, the Zeiss filter set used a BP450-490 excitation filter, 510 nm dichroic, and either a BP515-565 or a LP520 emission filter), although for some experiments filter sets that excited at lower wavelengths were used (for example, a Zeiss filter set with BP395-440 and LP470 filters and a 460 nm dichroic or with BP340-390 and LP400 filters with a 395 nm dichroic).
In some instances a xenon lamp appeared to give a more intense fluorescence than a mercury lamp when --WOsS/07463 PCT~S94110165 ~q ~9 a - 26 -cells were illuminated with light around 470 nm, although usually the results were comparable. No other attempts were made to enhance the signal (for example, by using low intensity light cameras) although this may be useful in some instances.
Previous experiments had shown that the native protein was fluorescent after glutaraldehyde fixation (W. W. Ward, unpub. data). S. Wang and T.
Hazelrigg (personal communicationi 23) have found that GFP fusion proteins in Drosophila melanogaster are fluorescent after formaldehyde fixation.
Applicants have confirmed that fluorescence persists after formaldehyde fixation with applicants' C.
elegans ~n i m~ 1 S and with recombinant GFP isolated from E. coli. The chemicals in nail polish, which is often used to seal cover slips, however, did appear to interfere with the C. elegans GFP
fluorescence.
lO. In the applicants' initial experiments, GFP was purified from 250 ml cultures of BL21(DE3)Lys S
bacteria containing TU#58; bacteria were grown in LB
broth (26) containing ampicillin (lO0 ~g/ml) and 0.8 mM IPTG. Induction was best when IPTG was present continually. Nevertheless, subsequent experiments with bacterial strain SMCl indicate that the bacteria could not grow in the constant presence of IPTG but can be induced by the IPTG during the log phase growth. The production of fluorescent protein is best at room temperature. Cells were washed in 4 ml of lO mM Tris-HCl (pH 7.4), lO0 mM NaCl, l mM
MgCl2, and lO mM dithiothreitol [A. Kumagai and W.
G. Dunphy, Cell 64, 903 (l99l)] and then sonicated (2 X 20 sec) in 4 ml of the same buffer containing WO95/07463 PCT~S94/10165 ~ - 27 - 2 1 6 9298 0.1 mM PMSF, pepstatin A (1 ~g/ml), leupeptin (1 ~g/ml), and aprotinin (2 ~g/ml), and centrifuged at 5,000 rpm for 5 min in the cold. The supernatant was centrifuged a second time (15,000 rpm for 15 min) and then diluted sevenfold with 10 mM Tris (pH
8.0), 10 mM EDTA, and 0.02~ NaN3. Corrected excitation and emission spectra were obtained with a SPEX FlT11 spectrofluorometer and compared with the purified L isoprotein form of GFP from A.
victoria (M. Cutler, A. Roth, and W. W. Ward, unpub.
data). The excitation spectra were measured from 300 - 500 nm with a fixed emission wavelength of 509 nm, and the emission spectra were measured from 410 - 600 nm with a fixed excitation of 395 nm. All spectra were recorded as signal-reference data (where the reference is a direct measurement of the lamp intensity with a separate photomultiplier tube) at room temperature with 1 ~ec integration times and 1 nm ir.crements. The spectral band widths were adjusted to 0.94 nm for all spectra.
11. Wild-type and mutant C. elegans animals were grown and genetic strains were constructed according to S.
Brenner, Genetics 77, 71 (1974).
The plasmid pGFP10.1 was used as a template for PCR
(with the 5' primer GAATAAAAGCTAGCAAAGATGAGTAAAG
(Sequence ID No. 2) and the 3' T3 primer) to generate a fragment with a 5' NheI site (at the start of translation) and a 3' EcoRI site (3' of the termination codon). The DNA was cut to produce an NheI - EcoRI fragment that was ligated into plasmid pPD 16.51 ( 12, 27), a vector containing the promoter of the C. elegans mec- 7 gene. Wild-type C. elegans were transformed by coinjecting this DNA (TU~64) and PCT~S94110165 w095/07463 ~9 ~ 28 -the DNA for plasmid pRF4, which contains the dominant rol-6 (sulOo6) mutation, into adult C.
elegans gonads as described by C. M. Mello, J. M.
Kramer, D. Stinchcomb, and V. Ambros, EMBO J. 10, 3959 (1991). A relatively stable line was isolated (TU1710) and the DNA it carried was integrated as described by Mitani et al . ( 15) to produce the integrated elements uIs3 and uIs4 (in strains TU1754 and TU1755, respectively).
Living C. elegans animals were mounted on agar (or agarose) pads as described (16), often with 10 mM
NaN3 as an anesthetic (28) (another nematode anesthetic, phenoxypropanol, quenched the fluorescence) and e~m;ned with either a Zeiss universal or axiophot microscope. For C. elegans, a long-pass emission filter works best because the animal's intestinal autofluorescence, (which increases as the animal matures), appears yellow (with band-pass filters the autofluorescence appears green and obscures the GFP fluorescence).
Because much more intense fluorescence was seen in uIs4 than uIs3 animals (for example, it was often difficult to see the processes of the ALM and PLM
cells in uIs3 animals when the animals were illuminated with a mercury lamp), the former have been used for the observations reported here. The general pattern of cell body fluorescence was the same in both strains and in the parental, nonintegrated strain (fluorescence in this strain was as strong as that in the uIs4 animals). The uIs4 animals, however, did show an unusual phenotype: both the ALM and PLM touch cells were often displaced anteriorly. The mature cells PCT~S94/10165 2 ~ 6~29~
usually had processes in the correct positions, although occasional cells had abnormally-projecting processes. These cells could be identified as touch receptor cells, because the fluorescence was dependent on mec-3, a homeobox gene that specifies touch cell fate (13, 15, 18, 28). mec-7 expression is reduced in the ALM touch cells of the head (but not as dramatically in the PLM touch cells of the tail) in mec-3 gene mutants ( 13, 1~) . Applicants find a similar change of GFP expression in a mec-3 mutant background for both uIs3 and uIs4. Thus, GFP
accurately represents the expression pattern of the mec- 7 gene. It is likely that the reduced staining in uIs3 ~nlm~l S and the misplaced cells in uIs4 animals is the result of either secondary mutations or the amount and position of the integrated DNA.
12. C. Savage, M. Hamelin, J. G. Culotti, A. Coulson, D.
G. Albertson, M. Chalfie, Genes Dev. 3, 870 (1989).
13. M. Hamelin, I. M. Scott, J. C. Way, J. G. Culotti, EMBO J. 11, 2885 (1992).
14. A. Duggan and M. Chalfie, unpub. data.
15. S. Mitani, H. P. Du, D. H. Hall, M. Driscoll, M.
Chalfie, Development 119, 773 (1993).
16. J. E. Sulston and H. R. Horvitz, Develop. Biol. 56, 110 (1977).
17. W. W. Walthall and M. Chalfie, Science 239, 643 (1988).
18. M. Chalfie and J. Sulston, Dev. Biol. 82, 358 W095/07463 PCT~S94/1016S
~9 ~q ~ - 30 -(1981).
19. In adults, the thicker size of the animals and the more intense autofluorescence of the intestine tend to obscure these cells.
20. These include several cells in the head (including the FLP cells) and tail~of newly hatched animals and the BDU cells, a pair of neurons just posterior to the pharynx. Expression of mec- 7 in these cells has been seen previously ( 13, 15) . The strongest staining of these non-touch receptor neurons are a pair of cells in the tail that have anteriorly directed processes that project along the dorsal muscle line. It is likely that these are the ALN
cells, the sister cells to the PLM touch cells [J.
G. White, E. Southgate, J. N. Thomson, and S.
Brenner, Philos. Trans. R. Soc. Lond. B Biol. Sci.
314, 1 (1986).]
21. The photobleaching with 395-440 nm light is further accelerated, to within seconds, in the presence of 10 mM NaN3, which is used as a C. elegans anesthetic (11). However, when cells in C. elegans have been photobleached, some recovery is seen within 10 min.
Further investigation is needed to determine whether this recovery represents de novo synthesis of GFP.
Rapid photobleaching (complete within a minute) of the green product was also seen when C. elegans was illuminated with 340-390 nm light. Unlike the photobleaching with 395-440 nm light, which abolished fluorescence produced by the 340-390 or 450-490 nm light, photobleaching with 340-390 nm light did not appear to affect the fluorescence produced by 395-490 or 450-490 nm light. Indeed, W095/07463 2 t 6 92 98 ~CT~S94/10l65 the fluorescence produced by 450-490 nm light appeared to be more intense after brief photobleaching by 340-390 nm light. This selective - photobleaching may indicate the production of more than one fluorescent product in the animal. These data on GFP fluorescence within E. coli and C.
elegans is in contrast to preliminary studies that suggest that the isolated native and E. coli proteins are very photostable. Applicants do not know whether this in vivo sensitivity to photobleaching is a normal feature of ~he jellyfish protein (the fluorescence in A. victoria has not been ~X~m; ned) or results from the absence of a necessary posttranslational modification unique to A. victoria or nonspecific damage within the cells.
22. Reviewed in T. J. Silhavy and ~. R. Beckwith, Microbiol. Rev. 49, 398 (1985); S. J. Gould and S.
Subramani, Anal. Biochem. 175, 5 (1988); and G. S.
A. B. Stewart and P. Williams, J. Gen. Microbiol.
138, 1289 (1992).
23. R. Heim, S. Emr, and R. Tsien (personal communication) have found that GFP expression in Saccharomyces cerevisiae can make the cells strongly fluorescent without causing toxicity. S. Wang and T. Hazelrigg (personal communication) have found that both C-terminal and N-terminal protein fusions with GFP are fluorescent in Drosophila melanogaster.
L. T ~n n 1 and F. McKeon (personal communication) have expressed a GFP protein fusion in m~mm~l ian (COS) cells. E. Macagno (personal communication) is expressing GFP in leeches. T. Hughes (personal communication) is expressing GFP in m~mm~l ian HEK293 cells.
PCT~S94/1016 ~6q~q8 - 32 -24. Applicants have generated several other plasmid constructions that may be useful to investigators.
These include a pBluescript II KS (+) derivative (TU#65) containing a KpnI - EcoRI fragment encoding GFP with an AgeI site 5' to the translation start and a BsmI site at the termination codon. Also available are gfp versions (TU#60 - TU#63) of the four C. elegans lacZ expression vectors (pPD16.43, pPD21.28, pPD22.04, and pPD22.11, respectively) described by Fire et al., 1990 (27) except that they lack the KpnI fragment containing the SV40 nuclear localization signal.
25. J. P. Miller and A. Selverston, Science 206, 702 (1979).
26. J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular cloning: A laboratory manual, 2nd Ed. Cold Spring Harbor Laboratcry Press, Cold Spring Harbor, New York, (1989).
27. A. Fire, S. W. Harrison, and D. Dixon, Gene 93, 189 (1990) .
28. J. C. Way and M. Chalfie, Cell 54, 5 (1988).
29. Chalfie, M., Tu. Y., Euskirchen, G., Ward, W.W., Prasher, D.C., Science 263, 8 02 (1994).
W 095/07463 2 1 6 ~ 2 9 8 PCT~US94/10165 SEQUENCE LIsTING
(1) GENERAL INFORMATION:
(i) APPLICANT: The Trustees of Columbia University in the City of New York and Woods Hole Oceanographic Institute (ii) TITLE OF INVENTION: USES OF GREEN FLUORESCENT PROTEIN
< 10 (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Cooper & Dunham (B) STREET: 30 Rockefeller Plaza (C) CITY: New York (D) STATE: New York (E) COUN1~Y: United States of America (F) ZIP: 10112 (v).COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version ~1.25 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
~viii) A~llOkN~Y/AGENT INFORMATION:
(A) NAME: White, John P.
(B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 0575/43557-B-PCT
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (212) 977-9550 (B) TELEFAX: (212) 664-0525 (C) TELEX: 422523 COOP UI
(2) INFORMATION FOR SEQ ID NO:l:
(i) S~:Qu~N~ CHARACTERISTICS:
(A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: 'inear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Escherichia coli (~i ) S~QU~N~ DESCRIPTION: SEQ ID NO:I:
ACAAAGGCTA GCA~AGGAGA AGAAC 25 W O9S/07463 PCTrUS94/10165 ~ ~ 6 9 ~ q ~ - 34 -(2) INFORMATION FOR SEQ ID NO:2:
(i) S~Q~:NL~: CHARACTERISTICS:
(A) LENGT~. 28 base pairs (B) TYPE: nucleic acid (C) sTR~Nn~nN~s single ~D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Escherichia coli (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Claims (36)
1. A cell comprising a DNA molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein operatively linked to a DNA sequence encoding the green fluorescent protein.
2. A cell of claim 1, wherein the cell is selected from a group consisting of bacterial cell, yeast cell, fungal cell, insect cell, nematode cell, or plant cell.
3. A cell of claim 1, wherein the cell is an animal cell.
4. A cell of claim 1, wherein the regulatory element is a promoter.
5. A cell of claim 4, wherein the promoter is activated by a heavy metal.
6. A cell of claim 4, wherein the promoter is that from a P450 gene.
7. A cell of claim 4, wherein the promoter is from a gene encoding a stress protein.
8. A cell of claim 7, wherein the stress protein is a heat-shock protein.
9. A cell of claim 4, wherein the promoter is from a gene required for cell viability.
10. A cell of claim 1, wherein the regulatory element is an enhancer.
11. A cell of claim 1, wherein the DNA sequence encodes the Aequorea victoria green fluorescent protein.
- 36a -
- 36a -
12. The cell of claim 11 designated SMC1 (ATCC Accession No. 69554).
13. An isolated green-fluorescent protein from the cell of claim 1.
14. A living organism comprising the cell of claim 1.
15. A living organism of claim 10, wherein the living organism is Caenorhabditis elegans.
16. A living organism of claim 15, wherein the regulatory element is for a stress protein.
17. A living organism of claim 16, wherein the stress protein is a heat-shock protein.
18. A method to produce green fluorescent protein comprising:
a) culturing the cell of claim 1; and b) isolating and purifying the green fluorescent protein produced from the cell.
a) culturing the cell of claim 1; and b) isolating and purifying the green fluorescent protein produced from the cell.
19. A method of claim 18, wherein the cell is an E. coli cell.
20. A method of claim 19, wherein the cell is cultured aerobically.
21. A method of claim 18 wherein the cell is designated SMC1 (ATCC Accession No. 69554).
22. A method for selecting cells expressing a protein of interest which comprises:
a) introducing into the cells a DNAI molecule having DNA sequence encoding the protein of interest and DNAII molecule having DNA sequence encoding a green fluorescent protein;
b) culturing the introduced cells under conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest.
a) introducing into the cells a DNAI molecule having DNA sequence encoding the protein of interest and DNAII molecule having DNA sequence encoding a green fluorescent protein;
b) culturing the introduced cells under conditions permitting expression of the green fluorescent protein and the protein of interest; and c) selecting the cultured cells which express green fluorescent protein, thereby selecting cells expressing the protein of interest.
23. A method of claim 22, wherein DNAI and DNAII are linked.
24. A method of claim 22, wherein the cells are selected from a group consisting essentially of bacterial cells, yeast cells, fungal cells, insect cells, nematode cells, plant or animal cells .
25. A method of claim 22, wherein the DNAII encodes the Aequorea victoria green fluorescent protein.
26. A method for localizing a protein of interest in a cell which comprises:
a) introducing into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein;
b) culturing the cell under conditions permitting expression of the fused protein; and c) detecting the location of the fused protein which composes the green fluorescent protein in the cell, thereby localizing a protein of interest in a cell.
a) introducing into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a green fluorescent protein such that the protein produced by the DNA molecule will have the protein of interest fused to the green fluorescent protein;
b) culturing the cell under conditions permitting expression of the fused protein; and c) detecting the location of the fused protein which composes the green fluorescent protein in the cell, thereby localizing a protein of interest in a cell.
27. A method of claim 26, wherein the cell normally expresses the protein of interest.
28. A method of claim 26, wherein the DNA encodes the Aequorea victoria green fluorescent protein.
29. A method for detecting expression of a gene in a cell which comprises:
a) introducing into the cell a DNA molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein;
b) culturing the cell in conditions permitting expression of the gene; and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
a) introducing into the cell a DNA molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein;
b) culturing the cell in conditions permitting expression of the gene; and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
30. A method for detecting expression of a gene in a subject which comprises:
a) introducing into a cell of the subject a DNA
molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein;
b) culturing the cell under conditions permitting expression of the fused protein; and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
a) introducing into a cell of the subject a DNA
molecule having DNA sequence of the gene linked to DNA sequence encoding a green fluorescent protein such that the regulatory element of the gene will control expression of the green fluorescent protein;
b) culturing the cell under conditions permitting expression of the fused protein; and c) detecting the expression of the green fluorescent protein in the cell, thereby indicating the expression of the gene in the cell.
31. A method of claims 29 or 30, wherein the DNA encodes the Aequorea victoria green fluorescent protein.
32. A method for determining the tissue-specificity of the transcription of a DNA sequence in a subject which comprises:
a) introducing into a cell of the subject a DNA
molecule having the DNA sequence linked to a DNA sequence encoding a green fluorescent protein such that the DNA sequence gene will control expression of the green fluorescent protein in the subject;
b) culturing the subject in conditions permitting the expression of the green fluorescent protein; and c) detecting the expression of the green fluorescent protein in different tissues of the subject, thereby determining the tissue-specificity of the DNA sequence.
a) introducing into a cell of the subject a DNA
molecule having the DNA sequence linked to a DNA sequence encoding a green fluorescent protein such that the DNA sequence gene will control expression of the green fluorescent protein in the subject;
b) culturing the subject in conditions permitting the expression of the green fluorescent protein; and c) detecting the expression of the green fluorescent protein in different tissues of the subject, thereby determining the tissue-specificity of the DNA sequence.
33. A method for detecting heavy metal in a solution which comprises:
a) culturing the cell of claims 4 or 5 in the solution; and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of heavy metal.
a) culturing the cell of claims 4 or 5 in the solution; and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of heavy metal.
34. A method for detecting pollutants in a solution which comprises:
a) culturing the cell of claims 4, 5, 6 or 7 in the solution; and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of a pollutant.
a) culturing the cell of claims 4, 5, 6 or 7 in the solution; and b) detecting expression of the green fluorescent protein, the expression of the green fluorescent protein indicates the presence of a pollutant.
35. A method for producing fluorescent molecular weight markers comprising:
a) linking a DNA molecule encoding a green fluorescent protein with a DNA molecule encoding a known amino acid sequence in the same reading frame;
b) introducing the linked DNA molecule of step a) in an expression system permitting the expression of a fluorescent protein encoded by the linked DNA molecule; and c) determining the molecular weight of the expressed fluorescent protein of step b), thereby producing a fluorescent protein molecular weight marker.
a) linking a DNA molecule encoding a green fluorescent protein with a DNA molecule encoding a known amino acid sequence in the same reading frame;
b) introducing the linked DNA molecule of step a) in an expression system permitting the expression of a fluorescent protein encoded by the linked DNA molecule; and c) determining the molecular weight of the expressed fluorescent protein of step b), thereby producing a fluorescent protein molecular weight marker.
36. A method of claim 35, further comprising purification of the expressed protein.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/119,678 US5491084A (en) | 1993-09-10 | 1993-09-10 | Uses of green-fluorescent protein |
US08/119,678 | 1993-09-10 | ||
US19227494A | 1994-02-04 | 1994-02-04 | |
US08/192,274 | 1994-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2169298A1 true CA2169298A1 (en) | 1995-03-16 |
Family
ID=26817579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002169298A Abandoned CA2169298A1 (en) | 1993-09-10 | 1994-09-09 | Uses of green fluorescent protein |
Country Status (9)
Country | Link |
---|---|
US (1) | US6146826A (en) |
EP (1) | EP0759170B1 (en) |
JP (1) | JP3810791B2 (en) |
KR (1) | KR960705209A (en) |
AT (1) | ATE400651T1 (en) |
AU (1) | AU694745B2 (en) |
CA (1) | CA2169298A1 (en) |
DE (1) | DE69435112D1 (en) |
WO (1) | WO1995007463A1 (en) |
Families Citing this family (240)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5777079A (en) * | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
DK1143011T3 (en) * | 1995-01-31 | 2006-03-20 | Bioimage As | Method for detecting biologically active substances |
DE69618350T2 (en) * | 1995-01-31 | 2002-09-19 | Bioimage As Soeborg | A METHOD FOR DETECTING BIOLOGICALLY ACTIVE SUBSTANCES |
US5958713A (en) * | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
GB9504446D0 (en) * | 1995-03-06 | 1995-04-26 | Medical Res Council | Improvements in or relating to gene expression |
ES2139329T3 (en) * | 1995-09-22 | 2000-02-01 | Bioimage A S | NEW VARIANTS OF GREEN FLUORESCENT PROTEIN, GFP. |
WO1997020931A1 (en) * | 1995-12-08 | 1997-06-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method and compositions for monitoring dna binding molecules in living cells |
US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US6803188B1 (en) | 1996-01-31 | 2004-10-12 | The Regents Of The University Of California | Tandem fluorescent protein constructs |
US6900304B2 (en) | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
US6077697A (en) | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
EP0904388A1 (en) * | 1996-04-19 | 1999-03-31 | Mycogen Plant Sciences, Inc. | MONITORING OF TRANSGENIC PLANTS WITH $i(IN VIVO) MARKERS |
AR006928A1 (en) | 1996-05-01 | 1999-09-29 | Pioneer Hi Bred Int | AN ISOLATED DNA MOLECULA CODING A GREEN FLUORESCENT PROTEIN AS A TRACEABLE MARKER FOR TRANSFORMATION OF PLANTS, A METHOD FOR THE PRODUCTION OF TRANSGENIC PLANTS, A VECTOR OF EXPRESSION, A TRANSGENIC PLANT AND CELLS OF SUCH PLANTS. |
US6096865A (en) * | 1996-05-06 | 2000-08-01 | Amgen Inc. | Mutants of the green fluorescent protein having improved fluorescent properties at 37° |
US6027881A (en) * | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US5989835A (en) | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
US5876711A (en) * | 1996-05-31 | 1999-03-02 | Onyx Pharmaceuticals, Inc. | Methods and compositions for determining the tumor suppressor status of cells |
US5925558A (en) * | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5912137A (en) | 1996-07-16 | 1999-06-15 | The Regents Of The University Of California | Assays for protein kinases using fluorescent |
US6593135B2 (en) | 1996-08-16 | 2003-07-15 | The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Long wavelength engineered fluorescent proteins |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
US6245564B1 (en) * | 1997-01-23 | 2001-06-12 | Cornell Research Foundation, Inc. | Method for separating cells |
US6727071B1 (en) | 1997-02-27 | 2004-04-27 | Cellomics, Inc. | System for cell-based screening |
DE69839501D1 (en) | 1997-02-27 | 2008-06-26 | Cellomics Inc | System for screening biological cells |
US7117098B1 (en) | 1997-02-27 | 2006-10-03 | Cellomics, Inc. | Machine-readable storage medium for analyzing distribution of macromolecules between the cell membrane and the cell cytoplasm |
US6197928B1 (en) | 1997-03-14 | 2001-03-06 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
US5998204A (en) * | 1997-03-14 | 1999-12-07 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
GB9706414D0 (en) * | 1997-03-27 | 1997-05-14 | Univ Manchester | Detection of DNA damage |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
PT986753E (en) * | 1997-04-07 | 2002-09-30 | Bioimage A S | METHOD PERMITTING TO EXTRACT QUANTITATIVE INFORMATION CONCERNING AN INFLUENCE EXERCISED ON A CELL RESPONSE |
US6046925A (en) * | 1997-04-14 | 2000-04-04 | The Regents Of The University Of California | Photochromic fluorescent proteins and optical memory storage devices based on fluorescent proteins |
DE19715683C2 (en) * | 1997-04-15 | 1999-11-11 | Max Planck Gesellschaft | New reporter vectors for one-hybrid and two-hybrid systems |
WO1999006570A2 (en) * | 1997-07-29 | 1999-02-11 | Unilever Plc | Plasmids |
GB2328209A (en) * | 1997-08-16 | 1999-02-17 | Stefan Andreas Oehler | Vectors which express a coloured protein for detection of integration into a cell |
WO1999037142A1 (en) * | 1998-01-27 | 1999-07-29 | Novo Nordisk A/S | Method for producing transgenic animals |
CN1796556A (en) | 1998-03-20 | 2006-07-05 | 联邦科学和工业研究组织 | Control of gene expression |
EP1925320A3 (en) | 1998-03-27 | 2008-09-03 | Prolume, Ltd. | Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
US7090976B2 (en) | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
JP2002527761A (en) * | 1998-10-15 | 2002-08-27 | バイオイメージ エイ/エス | An improved method for obtaining quantitative information on effects on cellular responses |
US20020164784A1 (en) * | 2000-10-27 | 2002-11-07 | Walke D. Wade | Novel human 7TM proteins and polynucleotides encoding the same |
EP1031630B1 (en) * | 1999-02-22 | 2004-10-20 | Matsushita Electric Industrial Co., Ltd. | Method for detecting bacteria |
US8148110B2 (en) | 1999-03-15 | 2012-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by β-lactamase reporter fragment complementation |
WO2001009177A2 (en) * | 1999-07-29 | 2001-02-08 | Whitehead Institute For Biomedical Research | Affinity fluorescent proteins and uses thereof |
US6716614B1 (en) * | 1999-09-02 | 2004-04-06 | Lexicon Genetics Incorporated | Human calcium dependent proteases, polynucleotides encoding the same, and uses thereof |
US6541252B1 (en) | 2000-05-19 | 2003-04-01 | Lexicon Genetics Incorporated | Human kinases and polynucleotides encoding the same |
EP1228233B1 (en) * | 1999-11-10 | 2007-01-10 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising renilla gfp |
WO2001042786A2 (en) | 1999-12-09 | 2001-06-14 | Cellomics, Inc. | System for cell based screening : cell spreading |
KR100414641B1 (en) | 2000-04-07 | 2004-01-13 | 동부한농화학 주식회사 | In vivo monitoring method of transgenic plants and system using the same |
JP2005518180A (en) | 2000-06-19 | 2005-06-23 | バイオイメージ エイ/エス | Novel fluorescent protein |
KR100393709B1 (en) * | 2000-08-07 | 2003-08-06 | 광주과학기술원 | Method for detecting environmental contaminant using recombinant animal cell line |
WO2002036633A2 (en) * | 2000-10-30 | 2002-05-10 | Lexicon Genetics Incorporated | Human 7tm proteins and polynucleotides encoding the same |
DE10136702B4 (en) | 2000-12-27 | 2004-04-22 | Axiogenesis Ag | System for cell and development specific selection of differentiating embryonic stem cells, adult stem cells and embryonic germline cells |
EP1236738A1 (en) * | 2001-02-23 | 2002-09-04 | Jungbauer, Alois, Professor Dr. | Internal standard for electrophoretic and chromatographic separation process |
JP3929250B2 (en) * | 2001-03-08 | 2007-06-13 | 株式会社ルネサステクノロジ | Semiconductor device |
WO2002077011A2 (en) * | 2001-03-12 | 2002-10-03 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Oxidation-reduction sensitive green fluorescent protein variants |
US20020188965A1 (en) | 2001-04-20 | 2002-12-12 | Zou-Yu Zhao | Methods of transforming plants |
BR0209745A (en) | 2001-05-30 | 2004-08-10 | Chromos Molecular Systems Inc | Artificial plant chromosomes, uses and same and method for preparing artificial plant chromosomes |
JP3829252B2 (en) | 2001-06-08 | 2006-10-04 | 独立行政法人理化学研究所 | Fluorescent protein |
US6894205B2 (en) * | 2001-06-22 | 2005-05-17 | Vanderbilt University | Assay for toxin induced neuronal degeneration and viability in C. elegans |
US7393656B2 (en) | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
US8048644B1 (en) | 2001-08-01 | 2011-11-01 | The University Of North Carolina At Charlotte | Biological indicator for monitoring the transport of micro-organisms in the environment |
WO2003014320A2 (en) | 2001-08-10 | 2003-02-20 | Cornell Research Foundation, Inc. | Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells |
CN1582332A (en) * | 2001-12-29 | 2005-02-16 | Seoul大学校产学协力财团 | GFP-transfected clon pig, GT knoc-out clon pig and methos for production thereof |
WO2003068357A2 (en) * | 2002-02-12 | 2003-08-21 | Cornell Research Foundation, Inc. | Identification and high-yield isolation of human pancreatic islet progenitor and stem cells |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
DE10256083A1 (en) * | 2002-11-29 | 2004-08-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Expression vector, process for the production of heterologous gene products and selection process for high-producing recombinant cells |
US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
WO2004113515A2 (en) | 2003-06-20 | 2004-12-29 | Axiogenesis Ag | Tissue modeling in embryonic stem (es) cell system |
ES2625486T3 (en) | 2003-08-25 | 2017-07-19 | Monsanto Technology Llc | Tubulin regulatory elements for use in plants |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
EP2361984A1 (en) | 2003-10-09 | 2011-08-31 | E. I. du Pont de Nemours and Company | Gene silencing by using modified micro-RNA molecules |
US7279275B2 (en) | 2003-11-03 | 2007-10-09 | Washington University | Methods and compositions for detection of segmented negative strand RNA viruses |
EP2868749B1 (en) | 2004-01-20 | 2017-10-04 | Monsanto Technology LLC | Chimeric promoters for use in plants |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
DK1740945T3 (en) | 2004-04-07 | 2019-01-21 | Ncardia Ag | KKE-INVASIVE, IN-VITRO FUNCTIONAL TISSUE TEST SYSTEMS |
ATE490306T1 (en) | 2004-05-11 | 2010-12-15 | Axiogenesis Ag | METHODS FOR DRUG DETECTION BASED ON IN VITRO DIFFERENTIATED CELLS |
US8603824B2 (en) | 2004-07-26 | 2013-12-10 | Pfenex, Inc. | Process for improved protein expression by strain engineering |
AU2005270968A1 (en) * | 2004-08-04 | 2006-02-16 | Merck Serono Sa | Capsules containing transfected cells, method for preparing the same and uses thereof for immunization and vaccination |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
PL1888641T3 (en) | 2005-05-18 | 2012-05-31 | Ablynx Nv | Serum albumin binding proteins |
HUE039846T2 (en) | 2005-05-20 | 2019-02-28 | Ablynx Nv | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
US8362250B2 (en) | 2005-05-24 | 2013-01-29 | Enzo Biochem, Inc. | Fluorescent dyes and compounds, methods and kits useful for identifying specific organelles and regions in cells of interest |
CA2617930A1 (en) | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
US8859846B2 (en) | 2005-09-21 | 2014-10-14 | E. I. Du Pont De Nemours And Company | Doubling of chromosomes in haploid embryos |
ES2399563T3 (en) * | 2005-11-04 | 2013-04-02 | Evrogen, Jsc | Modified fluorescent green proteins and method for their use |
WO2007127428A2 (en) | 2006-04-28 | 2007-11-08 | University Of Florida Research Foundation, Inc. | Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery |
US7855326B2 (en) * | 2006-06-06 | 2010-12-21 | Monsanto Technology Llc | Methods for weed control using plants having dicamba-degrading enzymatic activity |
BRPI0712484B1 (en) * | 2006-06-06 | 2017-06-06 | Monsanto Technology Llc | method for selecting transformed cells |
US20080004410A1 (en) * | 2006-06-30 | 2008-01-03 | Yu-Chin Lai | Hydrophilic macromonomers having alpha,beta-conjugated carboxylic terminal group and medical devices incorporating same |
EP2442108B1 (en) | 2006-07-14 | 2016-11-16 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
CN101522901A (en) | 2006-10-05 | 2009-09-02 | 纳幕尔杜邦公司 | Maize microRNA sequences |
CA2673331A1 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
US7838729B2 (en) | 2007-02-26 | 2010-11-23 | Monsanto Technology Llc | Chloroplast transit peptides for efficient targeting of DMO and uses thereof |
EP2142651B1 (en) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
US20090098594A1 (en) | 2007-08-21 | 2009-04-16 | Nodality, Inc. | Methods for diagnosis prognosis and methods of treatment |
ES2650224T3 (en) | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Human C-FMS antigen binding proteins |
US20090081715A1 (en) * | 2007-09-07 | 2009-03-26 | Cobalt Technologies, Inc., A Delaware Corporation | Engineered Light-Emitting Reporter Genes |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
US8088593B2 (en) | 2007-10-02 | 2012-01-03 | Theranos, Inc. | Modular point-of-care devices, systems, and uses thereof |
US8619257B2 (en) | 2007-12-13 | 2013-12-31 | Kimberley-Clark Worldwide, Inc. | Recombinant bacteriophage for detection of nosocomial infection |
EP4098661A1 (en) | 2007-12-26 | 2022-12-07 | Xencor, Inc. | Fc variants with altered binding to fcrn |
ES2562908T3 (en) | 2008-04-07 | 2016-03-09 | Monsanto Technology Llc | Plant regulatory elements and their uses |
AU2009235467A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Single variable domains against the Notch pathways |
EP2268825A4 (en) | 2008-04-09 | 2012-05-02 | Cobalt Technologies Inc | Immobilized product tolerant microorganisms |
US9334281B2 (en) * | 2008-09-08 | 2016-05-10 | Enzo Life Sciences, Inc. | Fluorochromes for organelle tracing and multi-color imaging |
US9250249B2 (en) | 2008-09-08 | 2016-02-02 | Enzo Biochem, Inc. | Autophagy and phospholipidosis pathway assays |
US8309306B2 (en) | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
ES2729320T3 (en) | 2008-12-19 | 2019-10-31 | Ablynx Nv | Genetic immunization to produce immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4 |
JO3382B1 (en) | 2008-12-23 | 2019-03-13 | Amgen Inc | Human cgrp receptor binding antibodies |
US8242248B2 (en) | 2009-03-23 | 2012-08-14 | Nodality, Inc. | Kits for multiparametric phospho analysis |
EP3461844A3 (en) | 2009-04-10 | 2019-05-15 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
EP2438087B1 (en) | 2009-06-05 | 2017-05-10 | Ablynx N.V. | Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
WO2010151706A1 (en) * | 2009-06-26 | 2010-12-29 | Cobalt Technologies, Inc. | Integrated system and process for bioproduct production |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
UA109888C2 (en) | 2009-12-07 | 2015-10-26 | ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES | |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
ES2916407T3 (en) | 2010-01-14 | 2022-06-30 | Monsanto Technology Llc | Regulatory elements of plants and their uses |
EP2558497A2 (en) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
EP3508854A1 (en) | 2010-04-27 | 2019-07-10 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
WO2012030738A2 (en) | 2010-08-30 | 2012-03-08 | Beckman Coulter, Inc. | Complex phosphoprotein activation profiles |
PT2611925T (en) | 2010-08-30 | 2018-03-02 | Dow Agrosciences Llc | Sugarcane bacilliform viral (scbv) enhancer and its use in plant functional genomics |
CN111982829A (en) | 2011-01-21 | 2020-11-24 | 拉布拉多诊断有限责任公司 | System and method for maximizing sample usage |
WO2012098260A1 (en) | 2011-01-21 | 2012-07-26 | Axiogenesis Ag | A non-viral system for the generation of induced pluripotent stem (ips) cells |
CA3004033C (en) | 2011-03-25 | 2020-08-18 | Monsanto Technology Llc | Plant regulatory elements and uses thereof |
WO2012155071A1 (en) | 2011-05-12 | 2012-11-15 | Gilead Biologics, Inc. | Methods of identifying lysyl oxidase - like - 2 (loxl2) binding partners |
CN107090455A (en) | 2011-05-13 | 2017-08-25 | 孟山都技术公司 | Plant control element and its application |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
US8435738B2 (en) | 2011-09-25 | 2013-05-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
JO3625B1 (en) | 2011-09-22 | 2020-08-27 | Amgen Inc | CD27L Antigen Binding Proteins |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
CA2858572C (en) | 2011-12-08 | 2023-01-17 | Amgen Inc. | Human lcat antigen binding proteins and their use in therapy |
AU2013202941B2 (en) | 2012-02-29 | 2015-06-25 | Dow Agrosciences Llc | Sugarcane bacilliform viral (SCBV) enhancer and its use in plant functional genomics |
US9663793B2 (en) | 2012-04-20 | 2017-05-30 | Monsanto Technology, Llc | Plant regulatory elements and uses thereof |
UY34813A (en) | 2012-05-18 | 2013-11-29 | Amgen Inc | ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER |
JP6388575B2 (en) | 2012-06-06 | 2018-09-12 | アメリカ合衆国 | Kit for detecting and monitoring endocrine disrupting substances (EDC) |
WO2014028939A2 (en) | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
WO2014036048A1 (en) | 2012-08-30 | 2014-03-06 | E. I. Du Pont De Nemours And Company | Long intergenic non-coding rnas in maize |
TW201425336A (en) | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
ES2728936T3 (en) | 2013-01-25 | 2019-10-29 | Amgen Inc | Antibodies directed against CDH19 for melanoma |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
US20140271629A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
EP2970446A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
WO2014144553A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
TW201525001A (en) | 2013-03-15 | 2015-07-01 | Amgen Res Munich Gmbh | Single chain binding molecules comprising N-terminal ABP |
EP2970470B1 (en) | 2013-03-15 | 2019-12-04 | Amgen Inc. | Human pac1 antibodies |
NZ753995A (en) | 2013-05-30 | 2022-07-01 | Kiniksa Pharmaceuticals Ltd | Oncostatin m receptor antigen binding proteins |
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
TWI688401B (en) | 2013-09-13 | 2020-03-21 | 美商安進公司 | Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia |
RU2019119857A (en) | 2014-02-20 | 2019-07-12 | Аллерган, Инк. | ANTIBODY TO C5 COMPLETE COMPONENT |
AU2015223056B2 (en) | 2014-02-27 | 2020-10-01 | Allergan, Inc. | Complement Factor Bb antibodies |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
US10690661B2 (en) | 2014-07-11 | 2020-06-23 | Northwestern University | Yeast-based biosensor |
UY36245A (en) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
JP6749312B2 (en) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | Optimized interspecific bispecific single chain antibody constructs |
EP3174903B1 (en) | 2014-07-31 | 2024-04-10 | Amgen Research (Munich) GmbH | Bispecific single chain antibody construct with enhanced tissue distribution |
DE102014012130B3 (en) | 2014-08-13 | 2015-03-05 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung | Detection method using recombinant living cells for the detection of xenobiotic substances and arrangement and test kit for performing the detection method |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
WO2016090323A1 (en) | 2014-12-05 | 2016-06-09 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
CA2975059C (en) | 2015-01-29 | 2023-02-21 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
JP6815322B2 (en) | 2015-02-04 | 2021-01-20 | モンサント テクノロジー エルエルシー | Plastid transformation method |
WO2016154631A1 (en) | 2015-03-26 | 2016-09-29 | The Texas A&M University System | Conversion of lignin into bioplastics and lipid fuels |
FI3283524T3 (en) | 2015-04-17 | 2023-05-05 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
WO2016189118A1 (en) | 2015-05-28 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of prognosis and treatment of patients suffering from acute myeloid leukemia |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
SG11201805255TA (en) | 2015-12-23 | 2018-07-30 | Amgen Inc | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
TWI797073B (en) | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | Pharmaceutical composition comprising bispecific antibody constructs |
AU2017216237B2 (en) | 2016-02-03 | 2024-04-04 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
RS62841B1 (en) | 2016-02-03 | 2022-02-28 | Amgen Res Munich Gmbh | Bcma and cd3 bispecific t cell engaging antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
JOP20170091B1 (en) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia |
WO2018004309A1 (en) | 2016-06-30 | 2018-01-04 | 김성천 | Double-stranded nucleic acid signal probe and method for detecting target molecule using same |
WO2018015389A1 (en) | 2016-07-18 | 2018-01-25 | University Of Bremen | Method of generating polyploid plants |
CN110177809B (en) | 2016-11-16 | 2023-11-03 | 埃博灵克斯股份有限公司 | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
JOP20190177A1 (en) | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018151868A2 (en) | 2017-02-16 | 2018-08-23 | Sonnet Bio Therapeutics | Albumin binding domain fusion proteins |
BR112019022751A2 (en) | 2017-05-05 | 2020-05-19 | Amgen Inc | pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
JOP20190259A1 (en) | 2017-05-31 | 2019-10-31 | Amgen Inc | Anti-jagged1 antigen binding proteins |
AR111842A1 (en) | 2017-06-02 | 2019-08-21 | Amgen Inc | PAC1 PEPTIDE ANTAGONISTS |
PE20200013A1 (en) | 2017-06-20 | 2020-01-06 | Amgen Inc | METHOD TO TREAT OR IMPROVE METABOLIC DISORDERS WITH GASTRIC INHIBITOR PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN COMBINATION WITH GLP-1 AGONISTS |
EP3661562A1 (en) | 2017-08-04 | 2020-06-10 | Amgen Inc. | Method of conjugation of cys-mabs |
TWI827570B (en) | 2017-12-11 | 2024-01-01 | 美商安進公司 | Continuous manufacturing process for bispecific antibody products |
TW201940518A (en) | 2017-12-29 | 2019-10-16 | 美商安進公司 | Bispecific antibody construct directed to MUC17 and CD3 |
WO2019139616A1 (en) | 2018-01-12 | 2019-07-18 | The Texas A&M University System | Increasing plant bioproduct yield |
TW202000238A (en) | 2018-02-26 | 2020-01-01 | 比利時商艾伯林克斯公司 | Improved nucleotide sequences encoding peptide linkers |
US20210301017A1 (en) | 2018-07-30 | 2021-09-30 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
MA53330A (en) | 2018-08-03 | 2021-06-09 | Amgen Inc | ANTIBODY CONSTRUCTIONS FOR CLDN18.2 AND CD3 |
CA3112792A1 (en) | 2018-09-14 | 2020-03-19 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
WO2020069303A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Antibodies against soluble bcma |
WO2020077212A1 (en) | 2018-10-11 | 2020-04-16 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
WO2020094609A1 (en) | 2018-11-06 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
US11542333B2 (en) | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
AU2020290573A1 (en) | 2019-06-13 | 2021-11-04 | Amgen Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
EP4028416A1 (en) | 2019-09-10 | 2022-07-20 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
CA3156683A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
BR112022018111A2 (en) | 2020-03-19 | 2022-10-25 | Amgen Inc | ANTIBODIES AGAINST MUCIN 17 AND USES THEREOF |
CA3178123A1 (en) | 2020-05-11 | 2021-11-18 | William Brondyk | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
EP4157874A2 (en) | 2020-05-29 | 2023-04-05 | Amgen Inc. | Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3 |
WO2022008488A1 (en) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of slamf1 as a biomarker in colorectal cancer |
WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
WO2022013256A1 (en) | 2020-07-15 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd160 as a biomarker in acute myeloid leukemia |
CR20230235A (en) | 2020-11-06 | 2023-10-05 | Amgen Res Munich Gmbh | POLYPEPTIDE CONSTRUCTIONS THAT SELECTIVELY BIND CLDN6 AND CD3 |
WO2022096698A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Polypeptide constructs binding to cd3 |
TW202233678A (en) | 2020-11-06 | 2022-09-01 | 德商安美基研究(慕尼黑)公司 | Polypeptides with enhanced clipping profile |
CN116323671A (en) | 2020-11-06 | 2023-06-23 | 安进公司 | Multi-targeting bispecific antigen binding molecules with increased selectivity |
CA3203106A1 (en) | 2021-01-20 | 2022-07-28 | Parag Mallick | Systems and methods for biomolecule quantitation |
AU2022246675A1 (en) | 2021-04-02 | 2023-10-19 | Amgen Inc. | Mageb2 binding constructs |
CA3217180A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
AU2022346234A1 (en) | 2021-09-17 | 2024-04-04 | University Of Freiburg | Proteins for regulation of symbiotic infection and associated regulatory elements |
US20230143932A1 (en) | 2021-09-20 | 2023-05-11 | University Of Freiburg | Pin6 proteins for the formation of nodule-like structures |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2024009146A2 (en) | 2022-07-05 | 2024-01-11 | University Of Freiburg | Plant regulatory elements and uses thereof |
WO2024052856A1 (en) | 2022-09-09 | 2024-03-14 | Friedrich Alexander Universität Erlangen-Nürnberg | Plant regulatory elements and uses thereof |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ214563A (en) * | 1984-12-31 | 1991-05-28 | Univ Georgia | Production of apoaeqorin using recombinant dna |
US5268463A (en) * | 1986-11-11 | 1993-12-07 | Jefferson Richard A | Plant promoter α-glucuronidase gene construct |
GB8916806D0 (en) * | 1989-07-22 | 1989-09-06 | Univ Wales Medicine | Modified proteins |
DK0680517T4 (en) * | 1993-01-21 | 2005-05-02 | Harvard College | Method and Diagnostic Kits to Determine the Toxicity of a Compound Using Mammalian Stress Promoters |
CA2157774A1 (en) * | 1993-04-07 | 1994-10-13 | Christopher John Marshall | Methods for screening of substances for therapeutic activity and yeast for use therein |
US5491084A (en) * | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
-
1994
- 1994-09-09 WO PCT/US1994/010165 patent/WO1995007463A1/en active Application Filing
- 1994-09-09 CA CA002169298A patent/CA2169298A1/en not_active Abandoned
- 1994-09-09 AU AU77957/94A patent/AU694745B2/en not_active Expired
- 1994-09-09 DE DE69435112T patent/DE69435112D1/en not_active Expired - Lifetime
- 1994-09-09 AT AT94928570T patent/ATE400651T1/en not_active IP Right Cessation
- 1994-09-09 US US08/367,236 patent/US6146826A/en not_active Expired - Lifetime
- 1994-09-09 JP JP50880195A patent/JP3810791B2/en not_active Expired - Lifetime
- 1994-09-09 KR KR1019960701205A patent/KR960705209A/en not_active Application Discontinuation
- 1994-09-09 EP EP94928570A patent/EP0759170B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69435112D1 (en) | 2008-08-21 |
US6146826A (en) | 2000-11-14 |
EP0759170A4 (en) | 1997-07-16 |
EP0759170A1 (en) | 1997-02-26 |
EP0759170B1 (en) | 2008-07-09 |
JP3810791B2 (en) | 2006-08-16 |
JPH09505981A (en) | 1997-06-17 |
KR960705209A (en) | 1996-10-09 |
WO1995007463A1 (en) | 1995-03-16 |
AU694745B2 (en) | 1998-07-30 |
AU7795794A (en) | 1995-03-27 |
ATE400651T1 (en) | 2008-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU694745B2 (en) | Uses of green fluorescent protein | |
US5491084A (en) | Uses of green-fluorescent protein | |
Chalfie | Green fluorescent protein | |
Levy et al. | Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells | |
EP0804457B1 (en) | Modified green fluorescenct proteins | |
WO1995021191A1 (en) | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein | |
JP2003527833A (en) | Chromophores / phosphors derived from flower insects and their use | |
RU2303600C2 (en) | New chromophores/fluorophores and uses thereof | |
Day et al. | Dual-function reporter protein for analysis of gene expression in living cells | |
WO1998021355A1 (en) | Mutants of green fluorescent protein | |
JP2009131260A (en) | Non-aggregating fluorescent protein and method for using the same | |
JP4060191B2 (en) | Green fluorescent protein mutant | |
JP2005526495A (en) | Novel fluorescent protein derived from Aequoreacoerulescens and method of use thereof | |
US7413874B2 (en) | Nucleic acid encoding fluorescent proteins from aquatic species | |
Kolb et al. | Synthesis and maturation of green fluorescent protein in a cell-free translation system | |
O'brochta et al. | Recent developments in transgenic insect technology | |
Chalfie | 1. A cell comprising a dna molecule having a regulatory element from a gene, other than a gene encoding a green fluorescent protein, operatively linked to a dna sequence encoding a fluorescent mutant of green fluorescent protein of Aequorea victoria. 20. A method for localizing a protein of interest in a cell which comprises: a) introducing into a cell a dna molecule having a sequence encoding the protein of interest linked to a dna sequence encoding a fluorescent mutant of green fluorescent protein of Aequorea victoria such that the protein produced by the dna molecule will have the protein of interest fused to the fluorescent mutant of green fluorescent protein of Aequorea victoria; b) culturing the cell under conditions permitting expression of the fused protein; and c) detecting the location of the fused protein, thereby localizing the protein of interest in the cell. | |
JP2010017186A (en) | Nucleic acid encoding linked chromo/fluorescent domain and method for using the same | |
Kim et al. | Truncated green fluorescent protein mutants and their expression in Aplysia neurons | |
Sullivan | Enlightening mitosis: construction and expression of green fluorescent fusion proteins | |
Smith et al. | Synthetic Biomimetic Fluorophores for Micro/Nanosensor | |
Prasher | Expression of red and green fluorescences in the same tissue | |
AU2002361624A1 (en) | Novel chromophores/fluorophores and methods for using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |